<!DOCTYPE html>
<html lang="zh-TW">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
<title>å©¦ç™Œè‡¨åºŠå°èˆª Ã— AI æ™ºèƒ½åˆ†æ 2026</title>
<link href="https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;500;700;900&family=Inter:wght@400;500;600;700&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">
<style>
:root{
--ink:#1a202c;--ink-soft:#2d3748;--ink-muted:#718096;
--cream:#f0f4f8;--white:#ffffff;
--primary:#2563eb;--primary-light:#dbeafe;--primary-dark:#1d4ed8;
--teal:#0891b2;--teal-light:#e0f2fe;
--green:#059669;--green-light:#d1fae5;
--orange:#d97706;--orange-light:#fef3c7;
--purple:#7c3aed;--purple-light:#ede9fe;
--red:#dc2626;--red-light:#fee2e2;
--gold:#d4a017;--gold-light:#fef9c3;
--border:#e2e8f0;--border-strong:#cbd5e0;
--shadow:0 1px 3px rgba(0,0,0,0.1),0 4px 16px rgba(0,0,0,0.06);
--shadow-lg:0 4px 24px rgba(0,0,0,0.12);--r:12px;}
*{margin:0;padding:0;box-sizing:border-box;}html{scroll-behavior:smooth;}
body{font-family:"Noto Sans TC","Inter",sans-serif;background:#f0f4f8;color:var(--ink);min-height:100vh;overflow-x:hidden;font-size:15px;line-height:1.6;-webkit-font-smoothing:antialiased;}
.site-header{background:#1e293b;position:sticky;top:0;z-index:200;border-bottom:3px solid var(--primary);box-shadow:0 2px 12px rgba(0,0,0,0.2);}
.header-inner{max-width:1400px;margin:0 auto;padding:12px 20px;display:flex;align-items:center;justify-content:space-between;gap:12px;flex-wrap:wrap;}
.logo-block{display:flex;align-items:center;gap:12px;}
.logo-icon{width:44px;height:44px;background:linear-gradient(135deg,#3b82f6,#1d4ed8);border-radius:12px;display:flex;align-items:center;justify-content:center;font-size:22px;flex-shrink:0;box-shadow:0 2px 8px rgba(59,130,246,0.4);}
.logo-title{font-family:"Noto Sans TC","Inter",sans-serif;font-weight:900;font-size:16px;font-weight:900;color:var(--gold);}
.logo-sub{font-size:11px;color:rgba(255,255,255,.5);font-family:"JetBrains Mono",monospace;margin-top:2px;}
.header-nav{display:flex;gap:4px;flex-wrap:wrap;}
.nav-btn{padding:8px 16px;border-radius:8px;border:1px solid rgba(255,255,255,.15);background:transparent;color:rgba(255,255,255,.75);font-size:13px;font-weight:600;cursor:pointer;transition:all .2s;}
.nav-btn:hover,.nav-btn.active{background:#3b82f6;color:white;border-color:#3b82f6;}
.page-content{max-width:1400px;margin:0 auto;padding:0 16px 40px;}
.tab-panel{display:none;}.tab-panel.active{display:block;}
.cancer-selector{padding:24px 0 0;}
.selector-label{font-size:12px;color:var(--ink-muted);font-family:"JetBrains Mono",monospace;margin-bottom:12px;letter-spacing:.06em;text-transform:uppercase;font-weight:600;}
.cancer-btns{display:flex;gap:10px;flex-wrap:wrap;}
.cancer-btn{padding:10px 22px;border-radius:100px;border:2px solid var(--border);background:white;color:var(--ink-soft);font-size:14px;font-weight:700;cursor:pointer;transition:all .2s;box-shadow:var(--shadow);}
.cancer-btn:hover{border-color:var(--primary);color:var(--primary);transform:translateY(-1px);box-shadow:var(--shadow-lg);}
.cancer-btn.active{background:var(--primary);color:white;border-color:var(--primary);box-shadow:0 2px 12px rgba(37,99,235,0.4);}
.stage-grid{display:grid;grid-template-columns:repeat(4,1fr);gap:16px;padding:20px 0;}
.stage-col{background:white;border-radius:16px;overflow:hidden;border:1px solid var(--border);box-shadow:var(--shadow-lg);}
.stage-header{padding:15px 18px;font-size:14px;font-weight:800;color:white;text-align:center;letter-spacing:0.02em;}
.stage-p-tx .stage-header{background:linear-gradient(135deg,#059669,#047857);}
.stage-p-mt .stage-header{background:linear-gradient(135deg,#2563eb,#1d4ed8);}
.stage-r-tx .stage-header{background:linear-gradient(135deg,#dc2626,#b91c1c);}
.stage-r-mt .stage-header{background:linear-gradient(135deg,#7c3aed,#6d28d9);}
.sub-section{border-bottom:1px solid #f1f5f9;padding:12px 14px;}
.sub-section:last-child{border-bottom:none;}
.sub-title{font-size:12.5px;font-weight:700;color:var(--ink);margin-bottom:5px;line-height:1.4;}
.sub-content{font-size:12px;color:var(--ink-muted);line-height:1.6;margin-bottom:8px;}
.trial-chip{display:block;width:100%;padding:9px 12px;margin-bottom:6px;border-radius:10px;border:1.5px solid #bfdbfe;background:#eff6ff;text-align:left;cursor:pointer;font-family:"JetBrains Mono",monospace;font-size:11px;color:#1d4ed8;font-weight:600;transition:all .18s;line-height:1.5;}
.trial-chip:hover{background:#dbeafe;border-color:#3b82f6;transform:translateX(3px);box-shadow:0 2px 8px rgba(37,99,235,0.15);}
.trial-chip.ongoing{color:#92400e;border-color:#fcd34d;background:#fffbeb;}
.chip-pharma{display:block;font-size:10px;opacity:.7;margin-top:3px;}
.detail-overlay{display:none;position:fixed;inset:0;background:rgba(26,26,46,.65);z-index:500;backdrop-filter:blur(4px);align-items:flex-start;justify-content:center;padding:20px 12px;overflow-y:auto;}
.detail-overlay.open{display:flex;}
.detail-modal{background:white;border-radius:20px;max-width:820px;width:100%;padding:32px;position:relative;border:1px solid var(--border);box-shadow:0 24px 80px rgba(0,0,0,0.2);animation:modalIn .25s cubic-bezier(.34,1.56,.64,1);margin:auto;}
@keyframes modalIn{from{transform:scale(.92) translateY(20px);opacity:0}to{transform:none;opacity:1}}
.modal-close{position:absolute;top:14px;right:14px;width:32px;height:32px;border-radius:50%;border:1.5px solid var(--border);background:white;cursor:pointer;font-size:16px;display:flex;align-items:center;justify-content:center;color:var(--ink-soft);}
.modal-close:hover{background:var(--ink);color:white;}
.modal-title{font-family:"Noto Sans TC","Inter",sans-serif;font-weight:900;font-size:18px;font-weight:900;color:var(--ink);margin-bottom:5px;padding-right:36px;line-height:1.3;}
.modal-meta{display:flex;gap:8px;flex-wrap:wrap;margin-bottom:18px;}
.modal-drug{font-family:"JetBrains Mono",monospace;font-size:12px;color:#0369a1;background:#e0f2fe;padding:4px 12px;border-radius:100px;font-weight:600;}
.modal-pharma{font-family:"JetBrains Mono",monospace;font-size:12px;color:#92400e;background:#fef3c7;padding:4px 12px;border-radius:100px;font-weight:600;}
.m-section{margin-bottom:16px;}
.m-label{font-size:11px;font-weight:700;letter-spacing:.08em;text-transform:uppercase;color:var(--ink-muted);margin-bottom:10px;font-family:"JetBrains Mono",monospace;padding-bottom:6px;border-bottom:2px solid var(--border);}
.m-result{background:#fffbeb;border-left:4px solid #f59e0b;padding:14px 16px;border-radius:10px;font-size:14px;line-height:1.8;color:var(--ink);}
.m-regimen{background:#f8fafc;border-left:4px solid #64748b;padding:14px 16px;border-radius:10px;font-size:12.5px;line-height:1.8;font-family:"JetBrains Mono",monospace;white-space:pre-wrap;color:#334155;}
.m-rationale{font-size:14px;line-height:1.85;color:var(--ink-soft);background:#f8fafc;padding:14px 16px;border-radius:10px;}
.criteria-grid{display:grid;grid-template-columns:1fr 1fr;gap:12px;}
.criteria-box{padding:12px;border-radius:10px;}
.criteria-box.inc{background:#f0fdf4;border:1.5px solid #86efac;}
.criteria-box.exc{background:#fff1f2;border:1.5px solid #fca5a5;}
.criteria-box h5{font-size:10px;font-weight:700;text-transform:uppercase;letter-spacing:.08em;margin-bottom:7px;font-family:"JetBrains Mono",monospace;}
.criteria-box.inc h5{color:#16a34a;}.criteria-box.exc h5{color:#dc2626;}
.criteria-box ul{padding-left:16px;}.criteria-box li{font-size:13px;line-height:1.7;margin-bottom:4px;}
.ai-panel{padding:28px 0 0;}
.ai-hero{text-align:center;margin-bottom:28px;}
.ai-hero h2{font-family:"Noto Sans TC","Inter",sans-serif;font-weight:900;font-size:26px;font-weight:900;color:var(--ink);margin-bottom:6px;}
.ai-hero p{font-size:14.5px;color:var(--ink-muted);line-height:1.8;max-width:580px;margin:0 auto;}
.ai-badge{display:inline-block;margin-top:12px;padding:6px 16px;background:#dbeafe;border:1px solid #93c5fd;border-radius:100px;font-size:12px;font-family:"JetBrains Mono",monospace;color:#1d4ed8;font-weight:600;}
.api-setup{background:#1e293b;border-radius:14px;padding:18px 22px;margin-bottom:20px;display:flex;align-items:center;gap:16px;flex-wrap:wrap;border:1px solid #334155;}
.api-setup-text h4{color:#93c5fd;font-size:13px;font-weight:700;margin-bottom:4px;}
.api-setup-text p{color:rgba(255,255,255,.5);font-size:11px;font-family:"JetBrains Mono",monospace;}
.api-input{flex:1;min-width:220px;padding:11px 16px;border-radius:10px;border:1.5px solid #475569;background:rgba(255,255,255,.08);color:white;font-family:"JetBrains Mono",monospace;font-size:12px;}
.api-input::placeholder{color:rgba(255,255,255,.28);}
.info-box{padding:12px 16px;border-radius:10px;font-size:12px;margin-bottom:14px;line-height:1.6;}
.info-box.tip{background:#e0f2fe;border:1px solid #7dd3fc;color:#0369a1;font-size:13px;}
.mode-tabs{display:flex;gap:6px;margin-bottom:14px;flex-wrap:wrap;}
.mode-tab{padding:10px 18px;border-radius:10px;border:2px solid var(--border);background:white;color:var(--ink-muted);font-size:13px;font-weight:700;cursor:pointer;transition:all .2s;}
.mode-tab:hover{border-color:var(--primary);color:var(--primary);}
.mode-tab.active{background:var(--primary);color:white;border-color:var(--primary);}
.input-area{background:white;border-radius:16px;border:1px solid var(--border);padding:24px;box-shadow:var(--shadow-lg);margin-bottom:20px;}
.text-input{width:100%;min-height:170px;border:2px solid #e2e8f0;border-radius:12px;padding:16px;font-family:"Noto Sans TC","Inter",sans-serif;font-size:14px;line-height:1.8;color:var(--ink);resize:vertical;background:#f8fafc;}
.text-input:focus{outline:none;border-color:#3b82f6;background:white;box-shadow:0 0 0 3px rgba(59,130,246,0.12);}
.text-input::placeholder{color:rgba(26,26,46,.32);}
.upload-zone{border:2px dashed rgba(201,168,76,.4);border-radius:12px;padding:32px;text-align:center;cursor:pointer;transition:all .2s;background:var(--cream);}
.upload-zone:hover{border-color:var(--teal);background:var(--teal-light);}
.upload-zone .uicon{font-size:32px;margin-bottom:10px;}
.upload-zone h4{font-size:14px;color:var(--ink-soft);margin-bottom:5px;font-weight:700;}
.upload-zone p{font-size:12px;color:var(--ink-muted);font-family:"JetBrains Mono",monospace;}
.upload-zone input{display:none;}
.upload-preview{display:none;align-items:center;gap:10px;background:var(--sage-light);padding:10px 14px;border-radius:10px;margin-top:10px;}
.upload-preview.show{display:flex;}
.upload-preview img{max-height:70px;border-radius:6px;}
.upload-preview span{font-size:11px;color:var(--sage);font-family:"JetBrains Mono",monospace;}
.struct-form{display:grid;grid-template-columns:1fr 1fr;gap:12px;}
.form-group{display:flex;flex-direction:column;gap:5px;}
.form-group label{font-size:11px;font-weight:700;color:var(--ink-muted);text-transform:uppercase;letter-spacing:.06em;font-family:"JetBrains Mono",monospace;}
.form-select,.form-text{padding:10px 13px;border-radius:10px;border:2px solid #e2e8f0;background:#f8fafc;color:var(--ink);font-size:13px;}
.form-select:focus,.form-text:focus{outline:none;border-color:var(--teal);}
.analyze-btn{width:100%;padding:17px;background:linear-gradient(135deg,#2563eb,#1d4ed8);color:white;border:none;border-radius:14px;font-size:16px;font-weight:800;cursor:pointer;transition:all .2s;display:flex;align-items:center;justify-content:center;gap:10px;box-shadow:0 4px 20px rgba(37,99,235,0.4);}
.analyze-btn:hover{transform:translateY(-2px);box-shadow:0 8px 28px rgba(37,99,235,0.5);}
.analyze-btn:disabled{opacity:.5;cursor:not-allowed;transform:none;}
.spinner{width:17px;height:17px;border:2px solid rgba(255,255,255,.3);border-top-color:white;border-radius:50%;animation:spin .8s linear infinite;}
@keyframes spin{to{transform:rotate(360deg)}}
.ai-result{display:none;background:white;border-radius:20px;border:1px solid var(--border);padding:32px;margin-top:24px;box-shadow:var(--shadow-lg);animation:fadeUp .4s ease;}
.ai-result.show{display:block;}
@keyframes fadeUp{from{opacity:0;transform:translateY(16px)}to{opacity:1;transform:none}}
.result-header{display:flex;align-items:center;gap:10px;margin-bottom:20px;flex-wrap:wrap;}
.gemini-badge{padding:5px 14px;background:linear-gradient(135deg,#4285f4,#1a73e8);color:white;border-radius:100px;font-size:12px;font-family:"JetBrains Mono",monospace;font-weight:600;}
.result-header h3{font-family:"Noto Sans TC","Inter",sans-serif;font-weight:900;font-size:18px;color:var(--ink);}
.result-content{font-size:15px;line-height:1.9;color:var(--ink-soft);}
.result-content h4{color:var(--primary);font-size:15px;font-weight:700;margin:20px 0 8px;padding-left:12px;border-left:4px solid var(--primary);}
.result-content ul{padding-left:18px;margin:6px 0;}
.result-content li{margin-bottom:5px;}
.result-content strong{color:var(--ink);}
.site-footer{text-align:center;padding:32px 16px;border-top:2px solid var(--border);color:var(--ink-muted);font-size:12px;font-family:"JetBrains Mono",monospace;line-height:2;background:white;margin-top:20px;}
@media(max-width:640px){
  .mobile-nav{display:flex;position:fixed;bottom:0;left:0;right:0;background:#1e293b;border-top:2px solid #3b82f6;z-index:300;padding:8px 0;}
  .mobile-nav-btn{flex:1;display:flex;flex-direction:column;align-items:center;gap:4px;background:none;border:none;color:rgba(255,255,255,.6);font-size:11px;font-weight:600;cursor:pointer;padding:8px 0;}
  .mobile-nav-btn.active{color:#93c5fd;}
  .mobile-nav-btn .micon{font-size:18px;}
  body{padding-bottom:70px;}
  .header-nav{display:none;}
}
@media(min-width:641px){.mobile-nav{display:none;}}
@media(max-width:1100px){.stage-grid{grid-template-columns:repeat(2,1fr);}}
@media(max-width:600px){.stage-grid{grid-template-columns:1fr;}.criteria-grid{grid-template-columns:1fr;}.struct-form{grid-template-columns:1fr;}}
</style>
</head>
<body>
<header class="site-header">
<div class="header-inner">
  <div class="logo-block">
    <div class="logo-icon">ğŸ©º</div>
    <div>
      <div class="logo-title">å©¦ç™Œè‡¨åºŠå°èˆªç³»çµ±</div>
      <div class="logo-sub">Gynecologic Oncology Navigator Â· 2026</div>
    </div>
  </div>
  <nav class="header-nav">
    <button class="nav-btn active" onclick="switchTab('nav',this)">ğŸ—º è©¦é©—å°èˆªåœ°åœ–</button>
    <button class="nav-btn" onclick="switchTab('ai',this)">ğŸ¤– AI æ‚£è€…åˆ†æ</button>
  </nav>
</div>
</header>
<nav class="mobile-nav">
  <button class="mobile-nav-btn active" id="mnav-nav" onclick="switchTab('nav',null,'mobile')">
    <span class="micon">ğŸ—º</span>è©¦é©—å°èˆª
  </button>
  <button class="mobile-nav-btn" id="mnav-ai" onclick="switchTab('ai',null,'mobile')">
    <span class="micon">ğŸ¤–</span>AI åˆ†æ
  </button>
</nav>
<div class="page-content">
<div id="tab-nav" class="tab-panel active">
  <div class="cancer-selector">
    <div class="selector-label">ç¬¬ä¸€æ­¥ï¼šé¸æ“‡ç™Œç—‡é¡å‹</div>
    <div class="cancer-btns">
      <button class="cancer-btn active" onclick="selectCancer('Endometrial',this)">ğŸ”´ å­å®®å…§è†œç™Œ</button>
      <button class="cancer-btn" onclick="selectCancer('Ovarian',this)">ğŸŸ£ åµå·¢ç™Œ</button>
      <button class="cancer-btn" onclick="selectCancer('Cervical',this)">ğŸŸ  å­å®®é ¸ç™Œ</button>
      <button class="cancer-btn" onclick="selectCancer('Uterine Sarcoma',this)">ğŸ”µ å­å®®è‚‰ç˜¤</button>
    </div>
  </div>
  <div id="stage-grid" class="stage-grid"></div>
</div>
<div id="tab-ai" class="tab-panel">
  <div class="ai-panel">
    <div class="ai-hero">
      <h2>AI æ‚£è€…è‡¨åºŠè·¯å¾‘åˆ†æ</h2>
      <p>è²¼ä¸Šæ‚£è€…ç—…æ­·æ‘˜è¦ï¼Œæˆ–ä¸Šå‚³ç—…ç†/å½±åƒç…§ç‰‡ï¼ŒGemini AI å°‡æ ¹æ“šå©¦ç™Œè©¦é©—è³‡æ–™åº«ï¼Œæ¨è–¦æœ€é©åˆçš„æ²»ç™‚è·¯å¾‘èˆ‡å¯åƒèˆ‡çš„è‡¨åºŠè©¦é©—ã€‚</p>
      <span class="ai-badge">âš¡ Powered by Google Gemini Â· éœ€è¼¸å…¥ API Key</span>
    </div>
    <div class="api-setup">
      <div class="api-setup-text">
        <h4>ğŸ”‘ Gemini API Key</h4>
        <p>å‰å¾€ aistudio.google.com å…è²»å–å¾—</p>
      </div>
      <input type="password" class="api-input" id="apiKey" placeholder="AIzaSyâ€¦">
    </div>
    <div class="info-box tip">ğŸ’¡ æ‚£è€…è³‡æ–™åƒ…åœ¨æ‚¨çš„ç€è¦½å™¨ä¸­è™•ç†ï¼Œä¸æœƒå„²å­˜æ–¼ä»»ä½•ä¼ºæœå™¨ã€‚</div>
    <div class="input-area">
      <div class="mode-tabs">
        <button class="mode-tab active" onclick="switchMode('text',this)">ğŸ“ æ–‡å­—è¼¸å…¥</button>
        <button class="mode-tab" onclick="switchMode('image',this)">ğŸ–¼ å½±åƒä¸Šå‚³</button>
        <button class="mode-tab" onclick="switchMode('form',this)">ğŸ“‹ çµæ§‹åŒ–è¡¨å–®</button>
      </div>
      <div id="mode-text">
        <textarea class="text-input" id="textInput" placeholder="è«‹è²¼ä¸Šæ‚£è€…ç—…æ­·æ‘˜è¦ï¼Œä¾‹å¦‚ï¼š&#10;&#10;æ‚£è€…å¥³æ€§ï¼Œ63æ­²ï¼Œå­å®®å…§è†œç™Œ Stage IIIC2ã€‚&#10;çµ„ç¹”å‹æ…‹ï¼šå­å®®å…§è†œæ¨£è…ºç™Œï¼ŒGrade 3ã€‚&#10;åˆ†å­åˆ†å‹ï¼šdMMRï¼ˆMLH1/PMS2ç¼ºå¤±ï¼‰ï¼Œp53 wild-typeï¼ŒPOLEæœªçªè®Šã€‚&#10;CA-125: 68 U/mLã€‚&#10;ç›®å‰è€ƒæ…®ä¸€ç·šåŒ–ç™‚æ–¹æ¡ˆï¼Œè©¢å•æ˜¯å¦å¯åŠ å…¥å…ç–«æ²»ç™‚æˆ–è‡¨åºŠè©¦é©—ã€‚"></textarea>
      </div>
      <div id="mode-image" style="display:none">
        <div class="upload-zone" onclick="document.getElementById('imgUpload').click()" id="uploadZone">
          <div class="uicon">ğŸ“·</div>
          <h4>é»æ“Šæˆ–æ‹–æ›³ä¸Šå‚³ç—…ç† / å½±åƒæª”æ¡ˆ</h4>
          <p>æ”¯æ´ JPG Â· PNG Â· WEBP Â· ç—…ç†åˆ‡ç‰‡ Â· CTæˆªåœ– Â· å ±å‘Šæƒæ</p>
          <input type="file" id="imgUpload" accept="image/*" onchange="handleImageUpload(event)">
        </div>
        <div class="upload-preview" id="uploadedPreview">
          <img id="previewImg" src="" alt="preview">
          <span id="previewName"></span>
        </div>
        <textarea class="text-input" id="imageContextInput" style="margin-top:12px;min-height:70px;" placeholder="è£œå……èªªæ˜ï¼ˆé¸å¡«ï¼‰ï¼šä¾‹å¦‚æ‚£è€…å¹´é½¡ã€è‡¨åºŠåˆ†æœŸã€å…¶ä»–æ¨™è¨˜ç­‰â€¦"></textarea>
      </div>
      <div id="mode-form" style="display:none">
        <div class="struct-form">
          <div class="form-group"><label>ç™Œç—‡é¡å‹</label>
            <select class="form-select" id="f-cancer">
              <option>å­å®®å…§è†œç™Œ (Endometrial)</option><option>åµå·¢ç™Œ (Ovarian)</option>
              <option>å­å®®é ¸ç™Œ (Cervical)</option><option>å­å®®è‚‰ç˜¤ (Uterine Sarcoma)</option>
            </select></div>
          <div class="form-group"><label>FIGO åˆ†æœŸ</label>
            <select class="form-select" id="f-stage">
              <option>Stage I</option><option>Stage II</option><option>Stage III</option><option>Stage IV</option><option>å¾©ç™¼</option>
            </select></div>
          <div class="form-group"><label>MMR ç‹€æ…‹</label>
            <select class="form-select" id="f-mmr">
              <option>dMMR / MSI-H</option><option>pMMR / MSS</option><option>æœªæª¢æ¸¬</option>
            </select></div>
          <div class="form-group"><label>p53 ç‹€æ…‹</label>
            <select class="form-select" id="f-p53">
              <option>wild-type</option><option>mutant (abn)</option><option>æœªæª¢æ¸¬</option>
            </select></div>
          <div class="form-group"><label>POLE çªè®Š</label>
            <select class="form-select" id="f-pole">
              <option>æœªçªè®Š</option><option>çªè®Š (exonuclease domain)</option><option>æœªæª¢æ¸¬</option>
            </select></div>
          <div class="form-group"><label>BRCA / HRDï¼ˆåµå·¢ç™Œï¼‰</label>
            <select class="form-select" id="f-brca">
              <option>BRCA1/2 çªè®Š</option><option>HRDé™½æ€§ï¼ˆBRCA wtï¼‰</option><option>HRDé™°æ€§</option><option>æœªæª¢æ¸¬</option>
            </select></div>
          <div class="form-group"><label>ECOG é«”èƒ½ç‹€æ…‹</label>
            <select class="form-select" id="f-ecog">
              <option>ECOG 0</option><option>ECOG 1</option><option>ECOG 2</option><option>ECOG â‰¥3</option>
            </select></div>
          <div class="form-group"><label>çµ„ç¹”å‹æ…‹</label>
            <input type="text" class="form-text" id="f-histo" placeholder="ä¾‹å¦‚ï¼šå­å®®å…§è†œæ¨£è…ºç™ŒG3ã€HGSCã€Clear cellâ€¦"></div>
          <div class="form-group" style="grid-column:1/-1"><label>æ—¢å¾€æ²»ç™‚å²</label>
            <input type="text" class="form-text" id="f-prior" placeholder="ä¾‹å¦‚ï¼šå»£æ³›å­å®®åˆ‡é™¤+éª¨ç›†æ·‹å·´æ¸…æƒï¼Œæœªæ›¾æ¥å—ç³»çµ±åŒ–ç™‚"></div>
          <div class="form-group" style="grid-column:1/-1"><label>å…¶ä»–é‡è¦æ¨™è¨˜ / ç‰¹æ®Šè€ƒé‡</label>
            <input type="text" class="form-text" id="f-markers" placeholder="ä¾‹å¦‚ï¼šHER2 2+, FRÎ±é«˜è¡¨ç¾, PD-L1 CPS, è…¹æ°´, è…åŠŸèƒ½â€¦"></div>
        </div>
      </div>
    </div>
    <button class="analyze-btn" id="analyzeBtn" onclick="runAnalysis()">
      <span id="btnIcon">âœ¨</span>
      <span id="btnText">å•Ÿå‹• Gemini AI åˆ†æ</span>
    </button>
    <div id="aiResult" class="ai-result">
      <div class="result-header">
        <span class="gemini-badge">GEMINI AI</span>
        <h3>è‡¨åºŠè·¯å¾‘åˆ†æå ±å‘Š</h3>
      </div>
      <div class="result-content" id="resultContent"></div>
    </div>
  </div>
</div>
</div>
<div class="detail-overlay" id="detailOverlay" onclick="closeModal(event)">
  <div class="detail-modal">
    <button class="modal-close" onclick="closeModal(null,true)">âœ•</button>
    <div class="modal-title" id="modalTitle"></div>
    <div class="modal-meta">
      <span class="modal-drug" id="modalDrug"></span>
      <span class="modal-pharma" id="modalPharma"></span>
    </div>
    <div class="m-section"><div class="m-label">æ ¸å¿ƒçµè«– Key Results</div><div class="m-result" id="modalResults"></div></div>
    <div class="m-section"><div class="m-label">ç§‘å­¸ç†æ“š Scientific Rationale</div><div class="m-rationale" id="modalRationale"></div></div>
    <div class="m-section"><div class="m-label">çµ¦è—¥æ–¹æ¡ˆ Regimen per Arm</div><div class="m-regimen" id="modalRegimen"></div></div>
    <div class="m-section"><div class="m-label">ç´å…¥ / æ’é™¤æ¨™æº–</div>
      <div class="criteria-grid">
        <div class="criteria-box inc"><h5>âœ… Inclusion</h5><ul id="modalInclusion"></ul></div>
        <div class="criteria-box exc"><h5>âŒ Exclusion</h5><ul id="modalExclusion"></ul></div>
      </div>
    </div>
  </div>
</div>
<footer class="site-footer">
  å©¦ç™Œè‡¨åºŠå°èˆªç³»çµ± Â· 2026 æ——è‰¦æ•´åˆç‰ˆ Â· åƒ…ä¾›é†«ç™‚å°ˆæ¥­äººå“¡åƒè€ƒä½¿ç”¨<br>
  All clinical data sourced from published trial results and ClinicalTrials.gov Â· Not for patient self-diagnosis
</footer>
<script>
const TRIALS=[
// ENDOMETRIAL
{c:"Endometrial",p:["P-TX","R-TX"],s:["dMMR / MSI-H / MMRd","pMMR / NSMP / MSS","Recurrent EC"],n:"RUBY (ENGOT-EN6/GOG-3031)",ph:"GSK",d:"Dostarlimab+CP",t:"p",pop:"æ™šæœŸè½‰ç§»ç¬¬ä¸€ç·šæˆ–å¾©ç™¼ï¼ŒdMMR HR 0.28ï¼›å…¨é«”HR 0.64ï¼›OS HR 0.69ã€‚ä¸€ç·šã€Œå…ç–«ï¼‹åŒ–ç™‚ã€æ–°æ¨™æº–ã€‚",rat:"PD-1 blockadeèˆ‡å«é‰‘åŒ–ç™‚å…·å”åŒICDæ•ˆæ‡‰ï¼Œè—‰ç”±åŒ–ç™‚èª˜å°è…«ç˜¤æŠ—åŸé‡‹æ”¾ï¼Œé‡å°MMRdæ—ç¾¤é”æˆæ¥µé«˜æŒä¹…æ‡‰ç­”ç‡ã€‚",reg:"Dostarlimab 500mg Q3W + Carboplatin AUC5 + Paclitaxel 175mg/mÂ² x6é€±æœŸ\nâ†’ ç¶­æŒ: Dostarlimab 1000mg Q6W æŒçºŒ3å¹´\nArm 2: Placebo + CP x6é€±æœŸ",inc:["æ–°è¨ºæ–·FIGO Stage III-IVæˆ–é¦–æ¬¡å¾©ç™¼EC","ECOG 0-1","å«Carcinosarcoma/Clear cell/Serous"],exc:["æ—¢å¾€PD-1/PD-L1æ²»ç™‚","æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…","æœªæ§åˆ¶æ„ŸæŸ“","CNSè½‰ç§»"],out:"dMMR 24m PFSç‡:61.4% vs 15.7%(HR 0.28,CI 0.16-0.50); ITT mOS HR 0.64(P=0.0021)"},
{c:"Endometrial",p:["P-TX","R-TX"],s:["dMMR / MSI-H / MMRd","pMMR / NSMP / MSS","Recurrent EC"],n:"NRG-GY018 (KEYNOTE-868)",ph:"MSD",d:"Pembrolizumab+CP",t:"p",pop:"Pembrolizumabï¼‹åŒ–ç™‚ä¸€ç·šå»¶é•·PFSï¼šdMMR HR 0.30ï¼›pMMR HR 0.54ã€‚æ”¹è®Šè‡¨åºŠå¯¦å‹™çš„é—œéµè©¦é©—ã€‚",rat:"ICIé‡å¡‘è…«ç˜¤å¾®ç’°å¢ƒï¼ŒPembrolizumabå¼·åŒ–ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰å¾Œçš„æŒä¹…æ€§ã€‚",reg:"Arm A: Pembrolizumab 200mg Q3W + Carbo AUC5 + Pacli 175mg/mÂ² x6é€±æœŸ\nâ†’ ç¶­æŒ: Pembrolizumab 400mg Q6W æŒçºŒ2å¹´\nArm B: Placebo + CP x6é€±æœŸ",inc:["Stage III/IVæˆ–å¾©ç™¼EC","MMR IHCæª¢æ¸¬","ECOG 0-1"],exc:["æ—¢å¾€antiâ€“PD-(L)1","æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚","CNSæ´»å‹•æ€§ç—…ç¶"],out:"dMMR PFS HR 0.30(CI 0.19-0.48); pMMR PFS HR 0.54(P<0.001)"},
{c:"Endometrial",p:["P-TX"],s:["pMMR / NSMP / MSS","dMMR / MSI-H / MMRd"],n:"DUO-E (ENGOT-EN9)",ph:"AstraZeneca",d:"Durvalumab+CP â†’ DurvaÂ±Ola",t:"p",pop:"Durva+åŒ–ç™‚ PFS HR 0.71ï¼›ä¸‰è—¥çµ„HR 0.55ï¼›pMMRä¸‰è—¥çµ„HR 0.57ï¼›OS HR 0.59ã€‚",rat:"PARPièˆ‡PD-L1æŠ‘åˆ¶åŠ‘åœ¨ç¶­æŒéšæ®µå”åŒæ•ˆæœï¼ŒPARPièª˜å°DNAæå‚·å¢åŠ æ–°æŠ—åŸè² è·ï¼Œå¼·åŒ–å…ç–«æ‡‰ç­”ã€‚",reg:"Arm 1: CP+placebo â†’ placeboç¶­æŒ\nArm 2: CP+Durvalumab â†’ Durvalumab 1500mg Q4Wç¶­æŒ\nArm 3: CP+Durvalumab â†’ Durvalumab 1500mg Q4W + Olaparib 300mg bidç¶­æŒ",inc:["æ–°è¨ºæ–·æ™šæœŸæˆ–å¾©ç™¼EC","é©åˆCP","ECOG 0-1"],exc:["æ—¢å¾€å…ç–«æ²»ç™‚/PARPi","æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚"],out:"pMMR Arm3 vs Arm1: PFS HR 0.57(CI 0.42-0.79); dMMR HR 0.42(0.22-0.80)"},
{c:"Endometrial",p:["P-TX","R-TX"],s:["dMMR / MSI-H / MMRd","Recurrent EC"],n:"AtTEnd (ENGOT-EN7)",ph:"Roche",d:"Atezolizumab+CP",t:"p",pop:"dMMRæ—ç¾¤PFS HR 0.36ï¼›æ•ˆç›Šä¸»è¦é›†ä¸­åœ¨dMMRï¼›pMMRæ•ˆç›Šç›¸å°ä¸æ˜é¡¯ã€‚ITT OS HR 0.82ã€‚",rat:"é©—è­‰ä¸€ç·šPD-L1æŠ‘åˆ¶åŠ‘ä½µç”¨åŒ–ç™‚å°æ™šæœŸæˆ–å¾©ç™¼æ‚£è€…ä¹‹ç”Ÿå­˜å„ªå‹¢ã€‚",reg:"Arm A: Atezolizumab 1200mg Q3W + CP x6-8é€±æœŸ â†’ ç¶­æŒAtezolizumab 1200mg Q3W\nArm B: Placebo + CP x6-8é€±æœŸ",inc:["Advancedæˆ–recurrent EC","ä¸€ç·šæ¥å—CP"],exc:["æ—¢å¾€PD-(L)1æŠ‘åˆ¶åŠ‘","æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚"],out:"dMMR PFS: NR vs 6.9m(HR 0.36,CI 0.23-0.57); å…¨äººç¾¤mOS HR 0.82(P=0.048)"},
{c:"Endometrial",p:["P-TX"],s:["p53 mutation (é«˜æ‹·è²å‹)","pMMR / NSMP / MSS","dMMR / MSI-H / MMRd"],n:"KEYNOTE-B21 (ENGOT-en11)",ph:"MSD",d:"Pembrolizumab+ChemoÂ±RT",t:"p",pop:"é«˜é¢¨éšªè¼”åŠ©æ²»ç™‚æŒ‘æˆ°ï¼šè¼”åŠ©åŒ–ç™‚åŠ å…¥Pembrolizumabä¸¦æœªé¡¯è‘—æ”¹å–„DFS(HR 1.02)ï¼Œç›®å‰ä¸å»ºè­°å¸¸è¦åŠ å…¥ã€‚",rat:"æ—¨åœ¨é©—è­‰é«˜é¢¨éšªå·²åˆ‡é™¤ECæ‚£è€…ï¼Œåœ¨è¼”åŠ©åŒ–ç™‚åŸºç¤ä¸ŠåŠ ICIæ˜¯å¦èƒ½é™ä½å¾©ç™¼é¢¨éšªã€‚",reg:"è©¦é©—çµ„: Pembrolizumab 200mg Q3W x6 + CP Â± æ”¾å°„æ²»ç™‚\nâ†’ ç¶­æŒ: Pembrolizumab 400mg Q6W x14é€±æœŸ",inc:["æ–°è¨ºæ–·é«˜é¢¨éšªä¸”å®Œå…¨åˆ‡é™¤EC","FIGO 2009 Stage I/II(Serous/Clear cell)æˆ–Stage III/IV","ECOG 0-1"],exc:["å…ˆå‰å…¨èº«æ€§æ²»ç™‚","æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…"],out:"2yr DFS: 75.2% vs 74.2%; HR 1.02(CI 0.79-1.32), P=0.57"},
{c:"Endometrial",p:["P-MT"],s:["Maintenance Therapy"],n:"DUO-E (Maint)",ph:"AstraZeneca",d:"DurvalumabÂ±Olaparibç¶­æŒ",t:"p",pop:"ç¶­æŒéšæ®µï¼šDurva+åŒ–ç™‚ PFS HR 0.71ï¼›ä¸‰è—¥çµ„HR 0.55ï¼›pMMRä¸‰è—¥çµ„HR 0.57ï¼›OS HR 0.59ã€‚",rat:"PARPièˆ‡PD-L1æŠ‘åˆ¶åŠ‘åœ¨ç¶­æŒéšæ®µå°pMMRæ‚£è€…çš„å”åŒå¢æ•æ•ˆæ‡‰ã€‚",reg:"Arm 2: Durvalumab 1500mg Q4Wç¶­æŒ\nArm 3: Durvalumab + Olaparib 300mg bidç¶­æŒ",inc:["ä¸€ç·šå«é‰‘åŒ–ç™‚å¾Œé”CR/PRä¹‹æ™šæœŸEC","æä¾›MMR IHCç‹€æ…‹"],exc:["å…ˆå‰æ¥å—éç³»çµ±æ€§IOæ²»ç™‚"],out:"pMMRä¸‰è—¥çµ„(Ola+Durva) PFS HR 0.57(CI 0.42-0.79)"},
{c:"Endometrial",p:["P-MT"],s:["Maintenance Therapy"],n:"SIENDO (ENGOT-EN5/GOG-3055)",ph:"Karyopharm",d:"Selinexor",t:"p",pop:"TP53 wild-typeæ—ç¾¤ç²ç›Šæ¥µä½³ï¼šç¶­æŒæ²»ç™‚é¡¯è‘—å»¶é•·PFSé”5å€ä»¥ä¸Š(27.4m vs 5.2m, HR 0.41)ã€‚",rat:"XPO1æŠ‘åˆ¶åŠ‘Selinexoråœ¨TP53 wild-typeæ‚£è€…ä¸­èª˜å°ç´°èƒæ ¸å…§æŠ‘ç™Œè›‹ç™½è“„ç©ï¼Œå¼•ç™¼è…«ç˜¤ç´°èƒå‡‹äº¡ã€‚",reg:"Selinexor 80mg æ¯é€±å£æœä¸€æ¬¡ï¼ŒæŒçºŒç›´åˆ°PDæˆ–ä¸å¯è€å—æ¯’æ€§",inc:["å®Œæˆä¸€ç·šå«é‰‘åŒ–ç™‚å¾Œé”CRæˆ–PRä¹‹æ™šæœŸ/å¾©ç™¼æ€§EC","ECOG 0-1","æä¾›çµ„ç¹”æ¨£æœ¬é€²è¡Œp53ç‹€æ…‹åˆ¤å®š"],exc:["å…ˆå‰æ¥å—XPO1æŠ‘åˆ¶åŠ‘æ²»ç™‚","æ´»å‹•æ€§è…¦è½‰ç§»","ç„¡æ³•ååš¥å£æœè—¥ç‰©"],out:"TP53 wild-type PFS: 27.4m vs 5.2m(HR 0.41, CI 0.23-0.73)"},
{c:"Endometrial",p:["R-TX"],s:["Recurrent EC"],n:"KEYNOTE-775 (Study 309)",ph:"MSD/Eisai",d:"Lenvatinib+Pembrolizumab",t:"p",pop:"å¾©ç™¼/æ™šæœŸECæ”¹å–„PFSèˆ‡OSï¼ˆpMMRï¼šPFS HR 0.60ã€OS HR 0.68ï¼›å…¨é«”ï¼šPFS HR 0.56ã€OS HR 0.62ï¼‰ã€‚",rat:"VEGF-TKIé‡å¡‘è¡€ç®¡ä¸¦æ¸›è¼•å…ç–«æŠ‘åˆ¶ï¼Œå…‹æœMSSè…«ç˜¤ä¹‹å…ç–«å†·å¾®ç’°å¢ƒã€‚",reg:"Lenvatinib 20mg QD + Pembrolizumab 200mg Q3W ç›´è‡³PDæˆ–ä¸å¯è€å—",inc:["Advanced/recurrent EC","å…ˆå‰è‡³å°‘ä¸€æ¬¡å«é‰‘åŒ–ç™‚é€²å±•ï¼ˆæœ€å¤šå‰ç·š2æ¬¡ï¼‰","ECOG 0-1","ä¸é™MMRç‹€æ…‹"],exc:["æ—¢å¾€PD-1/PD-L1","æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚","æœªæ§åˆ¶é«˜è¡€å£“","å‡ºè¡€/å»”ç®¡é«˜é¢¨éšª"],out:"pMMR OS: 17.4m vs 12.0m(HR 0.68, P<0.001); ITT OS: 18.3m vs 11.4m(HR 0.62)"},
{c:"Endometrial",p:["R-TX"],s:["Recurrent EC"],n:"GARNET",ph:"GSK",d:"Dostarlimab å–®è—¥",t:"p",pop:"å–®è‡‚ç ”ç©¶ã€‚dMMR ORR 45.5%; DORæœªé”åˆ°ã€‚pMMR ORRç´„10-15%ã€‚",rat:"é‡å°MSI-H/dMMRé«˜å…ç–«åŸæ€§æ‚£è€…ï¼Œå–®è—¥PD-1é˜»æ–·å³å¯é”æˆæŒä¹…æ‡‰ç­”ã€‚",reg:"Dostarlimab 500mg Q3W x4åŠ‘ â†’ 1000mg Q6W ç¶­æŒç›´åˆ°é€²å±•",inc:["Recurrent/advanced ECï¼Œå…ˆå‰æ²»ç™‚å¾Œ","åˆ†dMMR/MSI-Hèˆ‡pMMR cohort"],exc:["æ—¢å¾€PD-1/PD-L1","æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚"],out:"dMMR/MSI-H ORR 45.5%; DORæœªé”åˆ°; pMMR ORR~10-15%"},
{c:"Endometrial",p:["P-TX"],s:["dMMR / MSI-H / MMRd","pMMR / NSMP / MSS","POLE mutation (è¶…çªè®Šå‹)","p53 mutation (é«˜æ‹·è²å‹)"],n:"RAINBO Program",ph:"ENGOT/GOG",d:"åˆ†å­åˆ†å‹å°èˆªè¼”åŠ©æ²»ç™‚",t:"o",pop:"ç²¾æº–è¼”åŠ©æ²»ç™‚æ–°æ¨™æº–ï¼šæ ¹æ“šå››å¤§åˆ†å­åˆ†å‹é€²è¡Œæ²»ç™‚é™éšæˆ–å¢ç›Šï¼Œå„ªåŒ–è¡“å¾Œé å¾Œä¸¦æ¸›å°‘éåº¦æ²»ç™‚ã€‚",rat:"RAINBOç”±å››å¹³å°çµ„æˆï¼šRED(p53abnåŠ åŒ–æ”¾ç™‚)ã€GREEN(NSMPåŠ æ¿€ç´ )ã€AMBER(MMRdåŠ å…ç–«)ã€BLUE(POLEè§€å¯Ÿ)ã€‚",reg:"RED: åŒ–æ”¾ç™‚ + Olaparibç¶­æŒ\nGREEN: éª¨ç›†æ”¾ç™‚ + Letrozoleç¶­æŒ\nAMBER: éª¨ç›†æ”¾ç™‚ + Dostarlimabç¶­æŒ\nBLUE: è¡“å¾Œè§€å¯Ÿï¼ˆDe-escalationï¼‰",inc:["FIGO Stage I-III EC","è¡“å¾Œå®Œæˆåˆ†å­åˆ†å‹é‘‘å®š(POLE,MMR,p53)","å…·å‚™ä¸­é«˜é¢¨éšªç‰¹å¾µ"],exc:[],out:"è©¦é©—é€²è¡Œä¸­(Ongoing)ï¼ŒBLUEå¹³å°æ—¨åœ¨é©—è­‰POLEçªè®Šå¯å¦å…é™¤è¼”åŠ©æ²»ç™‚"},
{c:"Endometrial",p:["P-TX"],s:["pMMR / NSMP / MSS"],n:"PORTEC-4a",ph:"Leiden University",d:"Molecular-integrated Risk Profile",t:"p",pop:"åˆ†å­æ•´åˆé¢¨éšªå°èˆªï¼šæ¯”è¼ƒåˆ†å­é¢¨éšªæ¨¡å‹èˆ‡å‚³çµ±è‡¨åºŠç—…ç†é¢¨éšªå°èˆªçš„è¼”åŠ©æ”¾ç™‚ï¼Œé”æˆæ›´ç²¾æº–çš„æ‚£è€…åˆ†æµã€‚",rat:"é©—è­‰åŸºæ–¼åˆ†å­ç‰¹å¾µï¼ˆp53, POLE, MMR, CTNNB1, L1CAMï¼‰çš„é¢¨éšªè©•ä¼°æ˜¯å¦å„ªæ–¼å‚³çµ±è‡¨åºŠåˆ†æœŸã€‚",reg:"è©¦é©—çµ„: ä¾åˆ†å­é¢¨éšªæ¨¡å‹æ±ºå®šï¼ˆè§€å¯Ÿ/VBT/éª¨ç›†æ”¾ç™‚ï¼‰\nå°ç…§çµ„: ä¾å‚³çµ±è‡¨åºŠé¢¨éšªæ¨™æº–é€²è¡ŒVBT",inc:["FIGO Stage I EC","å…·å‚™ä¸­åº¦é¢¨éšªç—…ç†ç‰¹å¾µ","å®Œæˆå®Œæ•´åˆ†å­åˆ†å‹æ¨™è¨˜æª¢æ¸¬"],exc:[],out:"ä¸»è¦çµ‚é»ç‚ºé™°é“å¾©ç™¼ç‡ï¼›é æœŸåˆ†å­å°èˆªçµ„èƒ½æ¸›å°‘15%çš„éåº¦æ”¾ç™‚"},
{c:"Endometrial",p:["P-MT"],s:["Maintenance Therapy"],n:"MK2870-033",ph:"MSD",d:"Sac-TMT+Pembrolizumab",t:"o",pop:"ä¸€ç·špMMRç¶­æŒï¼šTROP2-ADC+PD-1è¯åˆç¶­æŒï¼Œè£œè¶³pMMRå…ç–«å–®è—¥åæ‡‰ä¸è¶³çš„ç¼ºå£ã€‚",rat:"æ¨™é¶Trop-2 ADC(Sac-TMT)å”åŒPD-1ï¼ŒADCèª˜å°ICDæ”¹å–„å¾®ç’°å¢ƒï¼Œæå‡pMMRæ‚£è€…ç¶­æŒéšæ®µæ‡‰ç­”æ·±åº¦ã€‚",reg:"Arm A: Sac-TMT 5mg/kg Q6W + Pembrolizumab 400mg Q6W ç¶­æŒè‡³PD\nArm B: é†«å¸«é¸æ“‡ç¶­æŒæ–¹æ¡ˆï¼ˆå°ç…§ï¼‰",inc:["æ–°è¨ºæ–·pMMR/MSS ECï¼ˆIHCç¢ºèªï¼‰","FIGO III-IVæœŸ","ä¸€ç·šCP+Pembroå¾ŒCR/PR"],exc:["å…ˆå‰ç³»çµ±æ€§IOæ²»ç™‚","çµ„ç¹”å­¸ç‚ºå­å®®è‚‰ç˜¤"],out:"æ‹›å‹Ÿä¸­(Ongoing)"},
{c:"Endometrial",p:["R-TX"],s:["Recurrent EC"],n:"GU-US-682-6769 (SG/Trodelvy)",ph:"Gilead",d:"Sacituzumab Govitecan",t:"o",pop:"é‰‘é¡+PD-(L)1å¾Œä»é€²å±•çš„å¾Œç·šç©ºçª—æœŸï¼šTROP2-ADCèƒ½å¦åœ¨PFS/OSè¶…è¶Šå–®è—¥åŒ–ç™‚ã€‚",rat:"TROP2æ¨™é¶ï¼ŒSN-38è¼‰è·å¼•ç™¼å¼·åŠ›DNAæå‚·ï¼Œå°ˆæ”»é‰‘é¡èˆ‡ICIå¤±æ•—å¾Œä¹‹å¾©ç™¼æ•‘æ´ã€‚",reg:"Sacituzumab govitecan 10mg/kg (D1, D8) Q21D ç›´è‡³PD",inc:["å¾©ç™¼æ€§ECï¼ˆä¸å«è‚‰ç˜¤ï¼‰","å…ˆå‰å«é‰‘åŒ–ç™‚åŠPD-1/L1å¤±æ•—é€²å±•","ECOG 0-1"],exc:[],out:"æ‹›å‹Ÿä¸­(Ongoing)"},
// OVARIAN
{c:"Ovarian",p:["P-TX"],s:["HGSC / Endometrioid"],n:"GOG-0218",ph:"Roche/GOG",d:"Chemo+Bevacizumab",t:"p",pop:"ä¸€ç·šæ¨™é¶åŸºçŸ³ï¼šåŠ å…¥Bevä¸¦æ¥çºŒç¶­æŒæ²»ç™‚èƒ½é¡¯è‘—å»¶é•·PFS(HR 0.72)ï¼Œå¥ å®šæ¨™é¶ç¶­æŒæ¨™æº–ã€‚",rat:"æŠ—è¡€ç®¡æ–°ç”Ÿè—¥ç‰©é˜»æ–·VEGFé€šè·¯ï¼Œåœ¨ä¸€ç·šåŒ–ç™‚æœŸé–“èˆ‡ä¹‹å¾ŒæŠ‘åˆ¶è…«ç˜¤æ–°ç”Ÿè¡€ç®¡é”åˆ°é•·æœŸæ§åˆ¶ã€‚",reg:"Bevacizumab 15mg/kg Q3W + Carbo/Pacli x6é€±æœŸ â†’ å–®è—¥Bevacizumabç¶­æŒè‡³ç¬¬22é€±æœŸ",inc:["æ–°è¨ºæ–·FIGO Stage IIIï¼ˆä¸å…¨åˆ‡é™¤ï¼‰æˆ–Stage IVä¸Šçš®æ€§åµå·¢ç™Œ","ECOG 0-2","æ¥å—éæ¸›ç©æ‰‹è¡“"],exc:["éä¸Šçš®æ€§åµå·¢ç™Œ","æœ‰è…¸ç©¿å­”ç—…å²æˆ–é«˜é¢¨éšª","å‚·å£æœªç™’åˆ"],out:"mPFS: 14.1m vs 10.3m(HR 0.717, P<0.001)"},
{c:"Ovarian",p:["P-TX"],s:["HGSC / Endometrioid"],n:"ICON7",ph:"Roche/ENGOT",d:"Chemo+Bevacizumab (Low Dose)",t:"p",pop:"ä¸€ç·šæ¨™é¶è­‰å¯¦ï¼šBev PFS HR 0.81ï¼Œé«˜é¢¨éšªæ—ç¾¤OSå»¶é•·ç²ç›Š(HR 0.64)ã€‚",rat:"é©—è­‰è¼ƒä½åŠ‘é‡Bev(7.5mg/kg)è¯ç”¨åŒ–ç™‚èˆ‡ç¶­æŒæ²»ç™‚çš„æœ‰æ•ˆæ€§èˆ‡å®‰å…¨æ€§ã€‚",reg:"Bevacizumab 7.5mg/kg Q3W + Carbo/Pacli x6é€±æœŸ â†’ å–®è—¥ç¶­æŒ12é€±æœŸ",inc:["FIGO Stage I-IIï¼ˆé«˜é¢¨éšªï¼‰æˆ–Stage III-IVä¸Šçš®æ€§åµå·¢ç™Œ","ä¸é™æ‰‹è¡“åˆ‡é™¤ç¨‹åº¦"],exc:["è‡¨åºŠé¡¯è‘—ä¹‹å¿ƒè¡€ç®¡ç–¾ç—…","è¿‘æœŸæœ‰é‡å¤§æ‰‹è¡“å²"],out:"PFS HR:0.81; é«˜é¢¨éšªæ—ç¾¤mOS: 39.7m vs 30.2m(HR 0.64)"},
{c:"Ovarian",p:["P-TX"],s:["HGSC / Endometrioid"],n:"BOOST / ENGOT-ov15",ph:"Roche/ENGOT",d:"Bev 15m vs 30m",t:"p",pop:"ç¶­æŒæ™‚ç¨‹å®šæ¡ˆï¼šBevç¶­æŒ30å€‹æœˆç›¸è¼ƒ15å€‹æœˆç„¡é¡å¤–ç”Ÿå­˜ç²ç›Š(HR 0.99)ã€‚",rat:"ç¢ºå®šBevacizumabåœ¨ä¸€ç·šç¶­æŒæ²»ç™‚çš„æœ€ä½³æŒçºŒæ™‚é–“ã€‚",reg:"æ§åˆ¶çµ„: Bev 15mg/kg Q3Wç¶­æŒ15å€‹æœˆ\nè©¦é©—çµ„: Bev 15mg/kg Q3Wç¶­æŒè‡³30å€‹æœˆ",inc:["æ–°è¨ºæ–·FIGO Stage IIB-IVä¸Šçš®æ€§åµå·¢ç™Œ","å®ŒæˆåŒ–ç™‚+Bevèª˜å°æ²»ç™‚è€…"],exc:["èª˜å°æœŸé–“ç–¾ç—…å·²é€²å±•","å°Bevacizumabä¸è€å—"],out:"mPFS: 24.2m vs 26.0m(HR 0.99, P=0.90)"},
{c:"Ovarian",p:["P-TX"],s:["Neoadjuvant Setting"],n:"van Driel HIPEC",ph:"NEJM",d:"Surgery+HIPEC(Cisplatin)",t:"p",pop:"é–“éš”æ¸›ç©æ‰‹è¡“åŠ å…¥HIPECå¯æ”¹å–„OS(HR 0.67)ã€‚IDSåŠ æº«ï¼šmOSå»¶é•·12å€‹æœˆã€‚",rat:"è¡“ä¸­åŠ æº«è…¹è…”åŒ–ç™‚å¼·åŒ–ç‰©ç†æ®ºå‚·èˆ‡æ»²é€åŠ›ã€‚",reg:"Stage III NACTå¾ŒIDSæ™‚åŒæ­¥åŠ æº«(42Â°C)è…¹è…”çŒæ³¨Cisplatin 100mg/mÂ² 90åˆ†é˜\nArm A: surgery+HIPEC+å¾ŒçºŒåŒ–ç™‚\nArm B: surgery(no HIPEC)+å¾ŒçºŒåŒ–ç™‚",inc:["Stage III epithelial ovarian cancer","NACTå¾Œé©åˆinterval debulking"],exc:["ä¸é©åˆå¤§æ‰‹è¡“æˆ–HIPECï¼ˆè…åŠŸèƒ½/å…¨èº«ç‹€æ³ç­‰ï¼‰"],out:"mOS: 45.7m vs 33.9m(HR 0.67, CI 0.48-0.94)"},
{c:"Ovarian",p:["P-TX"],s:["Neoadjuvant Setting"],n:"EORTC 55971 (NEJM 2010)",ph:"EORTC",d:"PDS vs NACT",t:"p",pop:"NACTéåŠ£æ•ˆæ€§é‡Œç¨‹ç¢‘ï¼šNACTå¾ŒIDSèˆ‡PDSç›¸æ¯”OSç›¸ç•¶ï¼Œä¸”æ‰‹è¡“ä½µç™¼ç—‡é¡¯è‘—é™ä½ã€‚",rat:"æ¢è¨å…ˆåŒ–ç™‚ç¸®å°è…«ç˜¤å¾Œå†æ‰‹è¡“æ˜¯å¦èƒ½é”æˆç›¸åŒé å¾Œä¸¦é™ä½é¢¨éšªã€‚",reg:"PDSçµ„: ç›´æ¥æ¸›ç©æ‰‹è¡“ â†’ å«é‰‘åŒ–ç™‚\nNACTçµ„: 3é€±æœŸåŒ–ç™‚ â†’ IDSæ‰‹è¡“ â†’ 3é€±æœŸåŒ–ç™‚",inc:["FIGO Stage IIICæˆ–IVä¸Šçš®æ€§åµå·¢ç™Œ/è…¹è†œç™Œ","ECOG 0-2","å…·å‚™çµ„ç¹”å­¸è­‰æ“š"],exc:[],out:"mOS: 30m(NACT) vs 29m(PDS)ï¼›NACTçµ„é‡å¤§ä½µç™¼ç—‡é¡¯è‘—è¼ƒå°‘"},
{c:"Ovarian",p:["P-TX"],s:["Neoadjuvant Setting"],n:"CHORUS (Lancet 2015)",ph:"MRC",d:"PDS vs NACT (UK Standard)",t:"p",pop:"NACTæ¨™æº–å†æ¬¡ç¢ºç«‹ï¼šç¢ºèªNACTéåŠ£æ–¼PDSï¼Œä¸”é¡¯è‘—æ¸›å°‘è¡“å¾Œ28å¤©å…§æ­»äº¡ç‡èˆ‡åš´é‡ä½µç™¼ç—‡ã€‚",rat:"åœ¨è‹±åœ‹é†«ç™‚é«”ç³»ä¸‹é©—è­‰EORTC 55971çµæœã€‚",reg:"NACTçµ„: 3é€±æœŸCP â†’ IDS â†’ 3é€±æœŸCP\nPDSçµ„: ç›´æ¥æ‰‹è¡“ â†’ 6é€±æœŸCP",inc:["æ™šæœŸä¸Šçš®æ€§åµå·¢ç™Œ","CTé¡¯ç¤ºè…«ç˜¤è² è·å¤§æˆ–é«”èƒ½ç‹€æ³è¼ƒå·®"],exc:[],out:"mOS: 24.1m(NACT) vs 22.6m(PDS)ï¼›NACTé¡¯è‘—æ”¹å–„ç”Ÿæ´»å“è³ªèˆ‡æ‰‹è¡“å®‰å…¨æ€§"},
{c:"Ovarian",p:["P-TX"],s:["Neoadjuvant Setting"],n:"SCORPION (Phase III)",ph:"Fagotti et al.",d:"NACT vs PDS (High Tumor Burden)",t:"p",pop:"é«˜è…«ç˜¤è² è·å°ç­–ï¼šFagottiè©•åˆ†â‰¥8è€…ï¼ŒNACTé¡¯è‘—é™ä½åœè¡“æœŸç™¼ç—…ç‡ä¸”ä¸å½±éŸ¿PFS/OSã€‚",rat:"åˆ©ç”¨è…¹è…”é¡Fagottiè©•åˆ†ç²¾æº–ç¯©é¸ç„¡æ³•é”æˆR0çš„é«˜é¢¨éšªæ‚£è€…ï¼Œæ¢è¨NACTçš„ä»‹å…¥åƒ¹å€¼ã€‚",reg:"NACTçµ„: å…ˆè¡ŒåŒ–ç™‚å¾Œé€²è¡ŒIDS\nPDSçµ„: å¼·åŠ›å˜—è©¦ç›´æ¥æ¸›ç©æ‰‹è¡“",inc:["æ™šæœŸåµå·¢ç™Œ","è…¹è…”é¡é ä¼°Fagottiè©•åˆ†â‰¥8"],exc:[],out:"é‡å¤§ä½µç™¼ç—‡ç‡: NACTçµ„é¡¯è‘—è¼ƒä½ï¼›PFSèˆ‡OSå…©çµ„ç„¡é¡¯è‘—çµ±è¨ˆå­¸å·®ç•°"},
{c:"Ovarian",p:["P-TX"],s:["Neoadjuvant Setting"],n:"JCOG0602",ph:"Japan Oncology",d:"NACT vs PDS (Japanese Data)",t:"p",pop:"æ—¥æœ¬å¯¦è­‰æ”¯æŒï¼šNACTå¯é¡¯è‘—ç¸®çŸ­æ‰‹è¡“æ™‚é–“ã€æ¸›å°‘å¤±è¡€é‡ï¼Œä¸¦é”æˆèˆ‡PDSç›¸ç•¶çš„ç”Ÿå­˜é å¾Œã€‚",rat:"åœ¨äºæ´²äººç¾¤ä¸­é©—è­‰NACTçš„éåŠ£æ•ˆæ€§ã€‚",reg:"NACTçµ„: 4é€±æœŸCP â†’ IDS â†’ 4é€±æœŸCP\nPDSçµ„: ç›´æ¥æ‰‹è¡“ â†’ 8é€±æœŸCP",inc:["FIGO Stage III/IVåµå·¢ç™Œ/è…¹è†œç™Œ","é ä¼°æ‰‹è¡“é›£åº¦é«˜"],exc:[],out:"mOS: 44.3m(NACT) vs 49.0m(PDS)ï¼›é”åˆ°éåŠ£æ•ˆæ€§çµ‚é»"},
{c:"Ovarian",p:["P-TX"],s:["Neoadjuvant Setting"],n:"TRUST (Ongoing)",ph:"ENGOT-ov33",d:"Quality-controlled PDS vs NACT",t:"o",pop:"é«˜å“è³ªæ‰‹è¡“æŒ‘æˆ°ï¼šåœ¨å…¨çƒé«˜å“è³ªæ‰‹è¡“ä¸­å¿ƒé‡æ–°è©•ä¼°PDSæ˜¯å¦å„ªæ–¼NACTï¼Œå‚™å—å­¸ç•ŒæœŸå¾…ã€‚",rat:"TRUSTè¦æ±‚æ¥µé«˜R0ç‡ï¼Œæ—¨åœ¨ç‚ºPDSé‡æ–°æ­£åã€‚",reg:"ç”±èªè­‰é«˜å“è³ªæ‰‹è¡“ä¸­å¿ƒé€²è¡Œéš¨æ©Ÿåˆ†é…ï¼Œåš´æ ¼åŸ·è¡Œæ ¹æ²»æ€§PDSæ‰‹è¡“",inc:["æ–°è¨ºæ–·Stage IIIB-IVBåµå·¢ç™Œ","ECOG 0-1"],exc:[],out:"è©¦é©—é€²è¡Œä¸­(Ongoing)ï¼›ä¸»è¦çµ‚é»ç‚ºOS"},
{c:"Ovarian",p:["P-TX"],s:["DDCT Setting"],n:"JGOG 3016",ph:"JGOG",d:"Dose-dense Paclitaxel",t:"p",pop:"åŠ‘é‡å¯†é›†åŒ–ç™‚é‡å¤§çªç ´ï¼šäºæ´²äººç¾¤ï¼Œæ¯é€±Paclitaxelé¡¯è‘—å»¶é•·PFS(28m vs 17m)èˆ‡OS(HR 0.75)ã€‚",rat:"æ›´é »ç¹çš„çµ¦è—¥é »ç‡ä¾†æŠ‘åˆ¶è…«ç˜¤è¡€ç®¡æ–°ç”Ÿä¸¦æ¸›å°‘è…«ç˜¤ç´°èƒåœ¨åŒ–ç™‚é–“æœŸçš„ä¿®å¾©æ©Ÿæœƒã€‚",reg:"Paclitaxel 80mg/mÂ² (D1,8,15) + Carboplatin AUC6(D1) Q21d x6é€±æœŸ",inc:["Stage II-IVä¸Šçš®æ€§åµå·¢ç™Œ/è…¹è†œç™Œ","å®Œæˆåˆæ­¥æ¸›ç©æ‰‹è¡“","ECOG 0-2"],exc:[],out:"mPFS: 28.2m vs 17.5m(HR 0.71); mOS: 100.5m vs 62.2m(HR 0.75)"},
{c:"Ovarian",p:["P-TX"],s:["DDCT Setting"],n:"GOG-262",ph:"GOG",d:"Weekly PaclitaxelÂ±Bev",t:"p",pop:"æ¨™é¶ä½µç”¨ä¹‹æ¬Šè¡¡ï¼šä¸ä½¿ç”¨Bevacizumabæ™‚æ¯é€±çµ¦è—¥é¡¯è‘—å»¶é•·PFSï¼›è‹¥ä½µç”¨æ¨™é¶ï¼Œå‰‡ç„¡é¡å¤–ç²ç›Šã€‚",rat:"åŒ—ç¾äººç¾¤é©—è­‰JGOG 3016çµæœï¼Œæ¢è¨Bevæ˜¯å¦å½±éŸ¿æ¯é€±åŒ–ç™‚æ–¹æ¡ˆå„ªå‹¢ã€‚",reg:"Weekly Paclitaxel 80mg/mÂ² æ¯é€± + Carboplatin AUC6 Q3Wï¼ŒÂ± Bevacizumab",inc:["Stage II-IVä¸Šçš®æ€§åµå·¢ç™Œ","ä¸é™æ‰‹è¡“åˆ‡é™¤ç¨‹åº¦"],exc:[],out:"ä¸å«Bevæ—ç¾¤PFS: 14.2m(Weekly) vs 10.3m(Q3W)ï¼›å«Bevæ—ç¾¤å…©çµ„ç„¡å·®ç•°"},
{c:"Ovarian",p:["P-TX"],s:["DDCT Setting"],n:"ICON8",ph:"GCIG/MRC",d:"Standard vs Weekly Pacli vs Weekly Carbo/Pacli",t:"p",pop:"æ­æ´²å¤§å‹å¯¦è­‰ï¼šæ¯é€±åŒ–ç™‚æ–¹æ¡ˆç›¸è¼ƒæ¨™æº–Q3Wä¸¦æœªå»¶é•·PFSã€‚",rat:"ä¸‰è‡‚éš¨æ©Ÿè©¦é©—ç¢ºå®šæ¯é€±å–®è—¥æˆ–é›™è—¥åŒ–ç™‚æ˜¯å¦æ‡‰æˆç‚ºä¸Šçš®æ€§åµå·¢ç™Œæ–°æ¨™æº–è¼”åŠ©æ²»ç™‚ã€‚",reg:"Arm 1: Q3Wæ¨™æº–æ–¹æ¡ˆ\nArm 2: Weekly Pacli 80mg/mÂ²+Q3W Carbo\nArm 3: Weekly Pacli 70mg/mÂ²+Weekly Carbo AUC2",inc:["Stage IC-IVä¸Šçš®æ€§åµå·¢ç™Œ","è¨ˆç•«æ¥å—è¼”åŠ©åŒ–ç™‚æˆ–NACT"],exc:[],out:"mPFS: Arm1(17.7m), Arm2(20.8m), Arm3(21.0m)ï¼›ä¸‰çµ„é–“ç„¡çµ±è¨ˆå­¸é¡¯è‘—å·®ç•°"},
{c:"Ovarian",p:["P-TX"],s:["DDCT Setting"],n:"MITO-7",ph:"MITO/ENGOT",d:"Low-dose Weekly Carbo/Pacli",t:"p",pop:"å»æ¯’å¼·åŒ–æ¨™æº–ï¼šæ¯é€±ä½åŠ‘é‡çµ„åˆé›–æœªå»¶é•·PFSï¼Œä½†é¡¯è‘—æå‡ç”Ÿæ´»å“è³ªä¸¦é™ä½è¡€æ¶²èˆ‡ç¥ç¶“æ¯’æ€§ã€‚",rat:"æ¢è¨æ›´æº«å’Œçš„æ¯é€±ä½åŠ‘é‡çµ„åˆæ˜¯å¦èƒ½ç¶­æŒç™‚æ•ˆä¸¦æ”¹å–„è€å—æ€§ã€‚",reg:"Paclitaxel 60mg/mÂ² + Carboplatin AUC2 åŒæ™‚æ¯é€±çµ¦è—¥ï¼Œå…±18é€±",inc:["Stage I-IVä¸Šçš®æ€§åµå·¢ç™Œ","ECOG 0-2"],exc:[],out:"mPFS: 17.3m vs 18.3m(P=0.66)ï¼›ç”Ÿæ´»å“è³ªé‡è¡¨æ•¸æ“šé¡¯è‘—å„ªæ–¼Q3Wçµ„"},
{c:"Ovarian",p:["P-TX"],s:["HGSC / Endometrioid"],n:"LION",ph:"NEJM",d:"No Lymphadenectomy",t:"p",pop:"ç³»çµ±æ€§æ·‹å·´æ¸…æƒä¸æ”¹å–„å­˜æ´»(OS HR 1.06ï¼›PFS HR 1.11)ä¸”ä½µç™¼ç—‡å¢åŠ ï¼Œæ”¹è®Šè‡¨åºŠé™°æ€§LNæ‚£è€…æ‰‹è¡“ç¯„å¼ã€‚",rat:"è‡¨åºŠ/å½±åƒé™°æ€§æ·‹å·´çµä¸”å®Œæˆè…«ç˜¤åˆ‡é™¤æ‚£è€…ï¼Œç³»çµ±æ€§æ¸…æƒæ˜¯å¦æœ‰ç”Ÿå­˜ç²ç›Šã€‚",reg:"Arm A: ç³»çµ±æ€§éª¨ç›†+è…¹ä¸»å‹•è„ˆæ—æ·‹å·´æ¸…æƒ\nArm B: ä¸æ¸…æƒæ·‹å·´çµ",inc:["Advanced ovarian cancer","Complete resection","æ·‹å·´çµè‡¨åºŠé™°æ€§"],exc:["æ˜é¡¯æ·‹å·´çµç—…ç¶","ç„¡æ³•è€å—æ‰‹è¡“å»¶é•·"],out:"OS HR 1.06ï¼ˆç„¡ç²ç›Šï¼‰ï¼›mOS: 65.5m vs 69.2m"},
{c:"Ovarian",p:["P-TX"],s:["IP Setting"],n:"GOG-172 (NEJM 2006)",ph:"GOG",d:"IP Cisplatin/Paclitaxel Gold Standard",t:"p",pop:"IPåŒ–ç™‚é»ƒé‡‘æ¨™æº–ï¼šStage IIIæ®˜é¤˜ç—…ç¶â‰¤1cmæ‚£è€…ï¼ŒOSé©šäººå»¶é•·é”16å€‹æœˆã€‚",rat:"ç¢ºèªR0/R1æ‰‹è¡“å¾Œï¼Œåˆä½µä½¿ç”¨IVèˆ‡IP Paclitaxel/Cisplatinæ˜¯æœ€æœ‰æ•ˆçš„è¼”åŠ©åŒ–ç™‚ç­–ç•¥ã€‚",reg:"D1: Paclitaxel 135mg/mÂ²(IV 24h)\nD2: Cisplatin 100mg/mÂ²(IP)\nD8: Paclitaxel 60mg/mÂ²(IP) Q3W x6",inc:["Stage IIIä¸Šçš®æ€§åµå·¢ç™Œ/è…¹è†œç™Œ","æœ€å„ªæ¸›ç©æ‰‹è¡“å¾Œï¼ˆæ®˜é¤˜ç—…ç¶â‰¤1cmï¼‰","ECOG 0-1"],exc:[],out:"mOS: 65.6m(IP) vs 49.7m(IV, P=0.03); mPFS: 23.8m vs 18.3m"},
{c:"Ovarian",p:["P-TX"],s:["IP Setting"],n:"GOG-252",ph:"GOG",d:"IP vs IV with Bevacizumab",t:"p",pop:"IPåœ°ä½é‡æª¢è¦–ï¼šæ‰€æœ‰çµ„åˆ¥å‡ä½µç”¨Bevæ™‚ï¼ŒIPèˆ‡IVçµ„PFSä¸¦ç„¡é¡¯è‘—å·®ç•°ä¸”IPçµ„æ¯’æ€§è¼ƒé«˜ã€‚",rat:"æ¢è¨åœ¨æ¨™é¶æ™‚ä»£ï¼ŒIPæŠ•è—¥æ¨¡å¼æ˜¯å¦ä»èƒ½ç¶­æŒå„ªæ–¼IVçš„ç”Ÿå­˜å„ªå‹¢ã€‚",reg:"ä¸‰çµ„å‡åŠ Bev:\n1. IV Carbo/Pacli\n2. IP Carbo/IV Pacli\n3. IP Cis/Pacli(æŒ‰GOG-172ä¿®æ”¹)",inc:["Stage II-IIIä¸Šçš®æ€§åµå·¢ç™Œ","æ®˜é¤˜ç—…ç¶â‰¤1cm","é©åˆä½¿ç”¨Bevacizumab"],exc:[],out:"mPFS: ä¸‰çµ„å‡è½åœ¨27-28å€‹æœˆï¼ˆç„¡çµ±è¨ˆå·®ç•°ï¼‰ï¼›IPçµ„å°ç®¡ç›¸é—œä½µç™¼ç—‡è¼ƒå¤š"},
{c:"Ovarian",p:["P-TX"],s:["IP Setting","Neoadjuvant Setting"],n:"OV21/PETROC (GCIG)",ph:"NCIC/GCIG",d:"IP Carboplatin vs IV",t:"p",pop:"IPè—¥ç‰©æ”¹è‰¯ç ”ç©¶ï¼šIP Carboplatinå…·æœ‰è‰¯å¥½è€å—æ€§ï¼Œä¸”åœ¨PFSä¸Šå±•ç¾å‡ºèˆ‡IP Cisplatinç«¶çˆ­çš„æ½›åŠ›(Phase II)ã€‚",rat:"åˆ©ç”¨æ¯’æ€§è¼ƒä½çš„Carboplatinå–ä»£Cisplatiné€²è¡Œè…¹è…”çµ¦è—¥ï¼Œè§£æ±ºGOG-172æ–¹æ¡ˆçš„é«˜æ¯’æ€§å•é¡Œã€‚",reg:"IPçµ„: Carboplatin AUC6 IP Q3W x6é€±æœŸ\nå°ç…§çµ„: IV Carboplatin",inc:["Stage II-IIIåµå·¢ç™Œ/è…¹è†œç™Œ","NACTå¾Œæ¥å—IDSè€…äº¦å¯å…¥æ¡ˆ"],exc:[],out:"PFS HR: 0.82(P=0.20)ï¼›NACTæ‚£è€…IPçµ„é¡¯ç¤ºè¼ƒä½³è…¹è†œæ§åˆ¶è¶¨å‹¢"},
{c:"Ovarian",p:["P-TX"],s:["Low grade serous carcinoma"],n:"NRG-GY019",ph:"NRG Oncology",d:"Letrozole vs Chemoâ†’Letrozole",t:"o",pop:"ä¸€ç·šå»åŒ–ç™‚æŒ‘æˆ°ï¼šè©•ä¼°æ–°è¨ºæ–·LGSOCæ‚£è€…ï¼Œå–®ç”¨Letrozoleæ˜¯å¦ä¸åŠ£æ–¼å‚³çµ±åŒ–ç™‚å¾Œæ¥çºŒç¶­æŒæ²»ç™‚ã€‚",rat:"LGSOCå°å‚³çµ±åŒ–ç™‚åæ‡‰ç‡è¼ƒä½ï¼Œé©—è­‰åˆæœŸå³ä½¿ç”¨å…§åˆ†æ³Œæ²»ç™‚çš„è‡¨åºŠæ•ˆç›Šã€‚",reg:"Arm 1: Letrozole 2.5mg QDå–®è—¥ç›´åˆ°é€²å±•\nArm 2: 6é€±æœŸåŒ–ç™‚(CP) â†’ Letrozoleç¶­æŒ",inc:["æ–°è¨ºæ–·Stage II-IV LGSOC/è…¹è†œç™Œ","ECOG 0-2"],exc:["æ›¾å—éå…¨èº«æ€§åŒ–ç™‚æˆ–æ¨™é¶æ²»ç™‚","è¨ˆç•«æ¥å—ç¶­æŒæ€§PARPi"],out:"æ‹›å‹Ÿä¸­(Ongoing)"},
{c:"Ovarian",p:["R-TX"],s:["PSOC (Sensitive Recur)"],n:"DESKTOP III",ph:"AGO",d:"Secondary Cytoreduction Surgery",t:"p",pop:"AGO Score+æ‚£è€…æ¬¡æ¸›ç©æ‰‹è¡“å¸¶ä¾†OSæ”¹å–„(HR 0.75)ã€‚R0åˆ‡é™¤mOS 53.7mã€‚",rat:"åš´é¸æ‚£è€…(AGO Scoreé™½æ€§)äºŒæ¬¡æ‰‹è¡“å…·ç”Ÿå­˜ç²ç›Šã€‚",reg:"æ‰‹è¡“çµ„: è…«ç˜¤å®Œå…¨åˆ‡é™¤æ‰‹è¡“ â†’ å«é‰‘åŒ–ç™‚\nåŒ–ç™‚çµ„: å–®ç´”å«é‰‘è¤‡æ–¹åŒ–ç™‚",inc:["é¦–æ¬¡é‰‘é¡æ•æ„Ÿå¾©ç™¼(PFI>6m)","AGO Scoreé™½æ€§(ECOG 0/ç„¡å¤§é‡è…¹æ°´/R0åˆ‡é™¤æ½›åŠ›)"],exc:["ç„¡æ³•é”åˆ°R0æˆ–æ‰‹è¡“é¢¨éšªéé«˜"],out:"ITT mOS: 53.7m vs 46.0m(HR 0.75, CI 0.59-0.96); R0åˆ‡é™¤mOS 61.9m"},
{c:"Ovarian",p:["R-TX"],s:["PSOC (Sensitive Recur)"],n:"Calypso Trial",ph:"ENGOT/GOG",d:"Carboplatin+PLD",t:"p",pop:"é‰‘æ•å¾©ç™¼å»æ¯’æ¨™æº–ï¼šCarbo/PLDåœ¨PFSä¸Šå„ªæ–¼Carbo/Pacliï¼Œä¸”å…·å‚™æ›´ä½³çš„è€å—æ€§ã€‚",rat:"ç‚ºé‰‘é¡æ•æ„Ÿå¾©ç™¼æ‚£è€…å°‹æ‰¾ç™‚æ•ˆç›¸ç•¶ã€æ¯’æ€§è¼ƒä½çš„åŒ–ç™‚çµ„åˆã€‚",reg:"Carboplatin AUC5 + PLD 30mg/mÂ² Q4W x6é€±æœŸ",inc:["é‰‘é¡æ•æ„Ÿå¾©ç™¼(PFI>6m)","å…ˆå‰åƒ…æ¥å—éä¸€ç·šå«é‰‘è¼”åŠ©åŒ–ç™‚"],exc:[],out:"mPFS: 11.3m vs 9.4m(HR 0.82, P=0.005)"},
{c:"Ovarian",p:["R-TX"],s:["PSOC (Sensitive Recur)"],n:"OCEANS",ph:"Roche/GOG",d:"Chemo+Bevacizumab (PSOC)",t:"p",pop:"é‰‘æ•å¾©ç™¼æ¨™é¶æ¨™æº–ï¼šåŠ å…¥Bevç¶­æŒæ²»ç™‚é¡¯è‘—å»¶é•·PFSé”4å€‹æœˆ(HR 0.48)ã€‚",rat:"åˆ©ç”¨æŠ—è¡€ç®¡æ–°ç”Ÿè—¥ç‰©å¼·åŒ–å«é‰‘è¤‡æ–¹åŒ–ç™‚(Gem/Carbo)çš„ç™‚æ•ˆä¸¦å»¶ç·©äºŒæ¬¡å¾©ç™¼ã€‚",reg:"Bevacizumab 15mg/kg Q3W + Gemcitabine/Carboplatin 6-10é€±æœŸ â†’ å–®è—¥ç¶­æŒè‡³é€²å±•",inc:["é¦–æ¬¡é‰‘é¡æ•æ„Ÿå¾©ç™¼(PFI>6m)","å…ˆå‰æœªæ¥å—éæŠ—è¡€ç®¡æ–°ç”Ÿæ²»ç™‚","å…·å‚™å¯æ¸¬é‡ç—…ç¶"],exc:["æ›¾å—éVEGFæŠ‘åˆ¶åŠ‘æ²»ç™‚","æœ‰è…¸æ¢—é˜»ç—‡ç‹€æˆ–ç—…å²"],out:"mPFS: 12.4m vs 8.4m(HR 0.484, P<0.0001)"},
{c:"Ovarian",p:["R-TX"],s:["PSOC (Sensitive Recur)"],n:"GOG-0213",ph:"Roche/GOG",d:"Chemo+Bevacizumab (OS Benefit)",t:"p",pop:"é‰‘æ•å¾©ç™¼OSçªç ´ï¼šåŠ å…¥Bevç¶­æŒæ²»ç™‚å¸¶ä¾†é¡¯è‘—OSç²ç›Š(mOSå»¶é•·ç´„5å€‹æœˆ)ã€‚",rat:"è©•ä¼°Bevacizumabè¯ç”¨Paclitaxel/Carboplatinå°PSOCæ‚£è€…çš„OSå½±éŸ¿ã€‚",reg:"Bevacizumab 15mg/kg Q3W + Pacli/Carbo â†’ å–®è—¥ç¶­æŒè‡³é€²å±•",inc:["é‰‘é¡æ•æ„Ÿå¾©ç™¼ä¸Šçš®æ€§åµå·¢ç™Œ","ECOG 0-1"],exc:[],out:"mOS: 42.6m vs 37.3m(HR 0.829, P=0.0447)"},
{c:"Ovarian",p:["R-TX"],s:["PSOC (Sensitive Recur)"],n:"MITO16B / ENGOT-ov17",ph:"Roche/ENGOT",d:"Bevacizumab Beyond PD",t:"p",pop:"æ¨™é¶è·¨ç·šæ²»ç™‚é¦–é¸ï¼šä¸€ç·šç”¨éBevå¾Œï¼Œå¾©ç™¼æ™‚æŒçºŒä½¿ç”¨Bevä»å…·é¡¯è‘—PFSç²ç›Š(HR 0.51)ã€‚",rat:"æŒ‘æˆ°æŠ—è¡€ç®¡æ–°ç”Ÿæ²»ç™‚çš„è€è—¥æ¦‚å¿µï¼Œé©—è­‰è·¨ç·šç¶­æŒæ˜¯å¦èƒ½æŒçºŒæŠ‘åˆ¶è…«ç˜¤è¡€ç®¡æ–°ç”Ÿã€‚",reg:"å«é‰‘è¤‡æ–¹åŒ–ç™‚ + Bevacizumab 15mg/kg Q3W â†’ å–®è—¥ç¶­æŒè‡³é€²å±•",inc:["ä¸€ç·šæ¥å—éBevæ²»ç™‚ä¹‹é‰‘æ•å¾©ç™¼æ‚£è€…","ECOG 0-1"],exc:[],out:"mPFS: 11.8m vs 8.8m(HR 0.51, CI 0.41-0.65)"},
{c:"Ovarian",p:["R-TX"],s:["PROC (Resistant Recur)"],n:"MIRASOL (GOG-3045)",ph:"ImmunoGen",d:"Mirvetuximab Soravtansine",t:"p",pop:"FRÎ±é«˜è¡¨ç¾PROCï¼šMirvetuximabè¼ƒåŒ–ç™‚æ”¹å–„PFSèˆ‡OSï¼ˆPFS HR 0.65ï¼›OS HR 0.67ï¼‰ã€‚ORR 42.3%ã€‚",rat:"é‡å°FRÎ±é«˜è¡¨ç¾PROCæ‚£è€…ï¼Œé¦–å€‹ADCç”Ÿå­˜ç²ç›Šç ”ç©¶ã€‚",reg:"FRÎ±-highæ—ç¾¤\nArm A: Mirvetuximab 6.0mg/kg(AIBW) IV Q3Wè‡³é€²å±•\nArm B: é†«å¸«é¸æ“‡åŒ–ç™‚ï¼ˆweekly paclitaxel/PLD/topotecanï¼‰",inc:["Platinum-resistanté«˜ç´šåˆ¥æ¼¿æ¶²æ€§ç‚ºä¸»","FRÎ±é«˜è¡¨ç¾"],exc:["ä¸ç¬¦åˆFRÎ±é–€æª»","ä¸å¯æ§çœ¼éƒ¨/ç¥ç¶“æ¯’æ€§é¢¨éšª"],out:"mOS: 16.4m vs 12.7m(HR 0.67); mPFS: 5.6m vs 4.0m(HR 0.65); ORR 42.3%"},
{c:"Ovarian",p:["R-TX"],s:["PROC (Resistant Recur)","PSOC (Sensitive Recur)"],n:"FRAmework-01 (LY4170156)",ph:"Eli Lilly",d:"LY4170156+Bevacizumab",t:"o",pop:"FRÎ± ADCè¯ç”¨anti-VEGFæ”»å…‹é‰‘æŠ—è—¥åµå·¢ç™Œï¼Œå½Œè£œé‰‘æŠ—è—¥æœŸæœ‰æ•ˆä¸”å¯è€å—ç³»çµ±æ²»ç™‚ä»ä¸è¶³çš„ç¼ºå£ã€‚",rat:"æ¨™é¶FRÎ± ADCè¯ç”¨anti-VEGFï¼Œåˆ©ç”¨Bevè¡€ç®¡èª¿ç¯€ä½œç”¨é™ä½è…«ç˜¤é–“è³ªå£“ï¼Œæå‡ADCæ»²é€æ·±åº¦ã€‚",reg:"PROC: Arm A: LY 3.0mg/kg+Bev 15mg/kg Q3W; Arm B: LY 4.0mg/kg+Bev Q3W\nPSOC(PFI 6-12m): Arm C: LY 3.0mg/kg+Bev Q3W\nå°ç…§(Arm D): é†«å¸«é¸æ“‡åŒ–ç™‚SoC",inc:["FRÎ±è¡¨é”é™½æ€§(IHC)","æœ€å¾Œé‰‘é¡å¾Œé€²å±•ä¹‹PROCæˆ–PSOC(PFI 90d-365d)"],exc:["æ›¾ç”¨éé‡å°FRÎ±ä¹‹ADC","æ´»å‹•æ€§é–“è³ªæ€§è‚ºç—…(ILD)"],out:"æ‹›å‹Ÿä¸­(Ongoing)"},
{c:"Ovarian",p:["R-TX"],s:["PROC (Resistant Recur)"],n:"AURELIA",ph:"Roche",d:"Bev+non-Platinum Chemo",t:"p",pop:"é‰‘æŠ—å¾©ç™¼åŸºçŸ³ï¼šé¦–å€‹è­‰æ˜Bevè¯ç”¨å–®è—¥åŒ–ç™‚èƒ½ä½¿PFSç¿»å€(6.7m vs 3.4m)ä¸”æ”¹å–„ç”Ÿæ´»å“è³ªã€‚",rat:"é‡å°é å¾Œæ¥µå·®çš„é‰‘é¡æŠ—è—¥å‹æ‚£è€…ï¼Œåˆ©ç”¨Bevå”åŒå‚³çµ±å–®è—¥åŒ–ç™‚å…‹æœè€è—¥æ€§ã€‚",reg:"Bevacizumab 10mg/kg Q2W æˆ– 15mg/kg Q3W + å–®è—¥åŒ–ç™‚(Pacli/PLD/Topotecan)",inc:["é‰‘é¡æŠ—è—¥å‹(PFI<6m)ä¸Šçš®æ€§åµå·¢ç™Œ","å…ˆå‰æ²»ç™‚ç·šæ•¸â‰¤2ç·š","ç„¡è…¸é“å—ç´¯é¢¨éšª"],exc:["å…ˆå‰ä¸€ç·šå³é€²å±•","æ´»å‹•æ€§è…¸é“ç–¾ç—…"],out:"mPFS: 6.7m vs 3.4m(HR 0.48, P<0.001)"},
{c:"Ovarian",p:["R-TX"],s:["Low grade serous carcinoma"],n:"GOG-281 / LOGS",ph:"Targeted",d:"Trametinib",t:"p",pop:"LGSOCæ¨™é¶é‡å¤§çªç ´ï¼šTrametinibé¡¯è‘—é™ä½52%ç–¾ç—…é€²å±•é¢¨éšª(HR 0.48)ï¼ŒORRé”26%ã€‚",rat:"é‡å°LGSOCä¸­å¸¸è¦‹çš„MAPKè·¯å¾‘ç•°å¸¸æ´»åŒ–ï¼Œåˆ©ç”¨MEKæŠ‘åˆ¶åŠ‘é€²è¡Œç²¾æº–æ¨™é¶é˜»æ–·ã€‚",reg:"Trametinib 2.0mg æ¯æ—¥å£æœä¸€æ¬¡ï¼ŒæŒçºŒç›´åˆ°PDæˆ–ä¸å¯è€å—",inc:["å¾©ç™¼æ€§LGSOC/è…¹è†œç™Œ","å…ˆå‰è‡³å°‘ä¸€æ¬¡å«é‰‘åŒ–ç™‚","ECOG 0-1"],exc:["æ›¾å—éå…¶ä»–MEKæŠ‘åˆ¶åŠ‘æ²»ç™‚","è‡¨åºŠé¡¯è‘—çš„å¿ƒè‡ŸåŠŸèƒ½ç•°å¸¸"],out:"mPFS: 13.0m vs 7.2m(HR 0.48, CI 0.36-0.64)"},
{c:"Ovarian",p:["R-TX"],s:["Low grade serous carcinoma"],n:"RAMP-201",ph:"Verastem Oncology",d:"Avutometinib+Defactinib",t:"o",pop:"LGSOCé›™é‡é˜»æ–·æ–°é«˜åº¦ï¼šKRASçªè®Šæ—ç¾¤ORRé«˜é”55%ï¼›å…¨é«”æ—ç¾¤ORRé”45%ã€‚",rat:"çµåˆRAF/MEKé›™é‡æŠ‘åˆ¶åŠ‘(Avutometinib)èˆ‡FAKæŠ‘åˆ¶åŠ‘(Defactinib)ï¼Œå…‹æœå–®ä¸€é€šè·¯é˜»æ–·å¾Œçš„è£œå„Ÿæ€§è€è—¥æ©Ÿåˆ¶ã€‚",reg:"Avutometinib 3.2mg(å…©æ¬¡/é€±) + Defactinib 200mg(å…©æ¬¡/æ—¥)\næ¡3é€±çµ¦è—¥1é€±ä¼‘æ¯ä¹‹é€±æœŸè¨­è¨ˆ",inc:["å¾©ç™¼æ€§LGSOCï¼ˆä¸é™KRASç‹€æ…‹ï¼‰","å…ˆå‰æ¥å—å«é‰‘åŒ–ç™‚åŠæ¨™é¶æ²»ç™‚"],exc:["æ´»å‹•æ€§è…¦è½‰ç§»","æ›¾å—éåŒé¡FAKæŠ‘åˆ¶åŠ‘æ²»ç™‚"],out:"KRAS mut ORR:55%; å…¨é«”ORR:45%ï¼ˆåˆæ­¥æ•¸æ“šï¼‰"},
{c:"Ovarian",p:["R-TX"],s:["Low grade serous carcinoma"],n:"GOG-3026",ph:"Novartis",d:"Ribociclib+Letrozole",t:"p",pop:"LGSOCå»åŒ–ç™‚çµ„åˆï¼šCDK4/6+AIï¼Œé”æˆORR 23%èˆ‡CBR 79%ã€‚mPFS 19.1mã€‚",rat:"å…§åˆ†æ³Œæ²»ç™‚é˜»æ–·æ¿€ç´ å—é«”ï¼Œå”åŒCDK4/6æŠ‘åˆ¶åŠ‘é”æˆæ›´å¼·çš„ç´°èƒé€±æœŸåœæ»¯æ•ˆæ‡‰ã€‚",reg:"Ribociclib 400mg QDï¼ˆé€£æœ3é€±ä¼‘æ¯1é€±ï¼‰+ Letrozole 2.5mg QDï¼ˆæŒçºŒæ¯æ—¥å£æœï¼‰",inc:["å¾©ç™¼æ€§LGSOC","ER/PRé™½æ€§è¡¨é”è€…å„ªå…ˆ","ä¸é™å…ˆå‰æ²»ç™‚ç·šæ•¸"],exc:["ç„¡æ³•ååš¥å£æœè—¥ç‰©","ä½µç”¨å¼·æ•ˆCYP3A4èª˜å°åŠ‘"],out:"mPFS: 19.1m; ORR:23%; CBR:79%"},
{c:"Ovarian",p:["R-TX"],s:["Low grade serous carcinoma"],n:"MILO / ENGOT-ov11",ph:"Array BioPharma",d:"Binimetinib",t:"p",pop:"LGSOCæ¨™é¶æ¢ç´¢ï¼šMEKæŠ‘åˆ¶åŠ‘Binimetinib vsåŒ–ç™‚ï¼Œè©¦é©—å› ç„¡æ•ˆæ€§æ—©æœŸåœæ­¢ã€‚",rat:"é‡å°LGSOCå¸¸è¦‹ä¹‹MAPKé€šè·¯æ¿€æ´»ï¼Œå˜—è©¦åˆ©ç”¨å–®è—¥MEKæŠ‘åˆ¶åŠ‘é”æˆæ§åˆ¶ã€‚",reg:"Binimetinib 45mg æ¯æ—¥å£æœå…©æ¬¡ vs é†«å¸«é¸æ“‡åŒ–ç™‚(PLD/Pacli/Topo)",inc:["å¾©ç™¼æ€§LGSOC","å…ˆå‰è‡³å°‘ä¸€ç·šå«é‰‘åŒ–ç™‚","ä¸é™KRAS/BRAFç‹€æ…‹"],exc:[],out:"mPFS: 9.1m vs 10.6m, HR 1.21ï¼ˆæœªé”é æœŸç²ç›Šï¼‰"},
{c:"Ovarian",p:["P-TX"],s:["Clear Cell Carcinoma"],n:"JGOG3017 / GCIG",ph:"JGOG",d:"Irinotecan+Cisplatin vs TC",t:"p",pop:"OCCCä¸€ç·šæ¨™æº–æŒ‘æˆ°ï¼šIrinotecan/Cisplatin vs TCæ–¹æ¡ˆï¼ŒPFSæˆ–OSç„¡é¡¯è‘—å·®ç•°ã€‚",rat:"è€ƒé‡OCCCå°Paclitaxelè¼ƒä¸æ•æ„Ÿï¼Œå˜—è©¦åˆ©ç”¨å°OCCCå…·æ½›åœ¨æ´»æ€§çš„Irinotecanæ–¹æ¡ˆã€‚",reg:"Arm A: Irinotecan 60mg/mÂ²(D1,8,15)+Cisplatin 60mg/mÂ²(D1) Q4W\nArm B: Carboplatin AUC6+Paclitaxel 175mg/mÂ² Q3W",inc:["æ–°è¨ºæ–·FIGO Stage I-IVæ˜ç´°èƒç™Œ(OCCC)","ECOG 0-2"],exc:[],out:"2yr PFS: 63.0% vs 67.3%; mOS HR:1.06(P=0.72)"},
{c:"Ovarian",p:["R-TX"],s:["Clear Cell Carcinoma"],n:"MoST-CIRCUIT",ph:"Garvan Institute",d:"Nivolumab+Ipilimumab",t:"p",pop:"OCCCå…ç–«é›™é˜»æ–·ï¼šé›£æ²»å‹OCCCï¼ŒNivo+Ipiå±•ç¾äº®çœ¼ORR(24%)èˆ‡æŒä¹…ç–¾ç—…æ§åˆ¶(CBR 52%)ã€‚",rat:"OCCCå…·å‚™ç‰¹å®šçš„å…ç–«æŠ‘åˆ¶ç’°å¢ƒï¼ŒPD-1èˆ‡CTLA-4é›™é‡é˜»æ–·æ¿€ç™¼æ›´å¼·Tç´°èƒæŠ—è…«ç˜¤åæ‡‰ã€‚",reg:"Nivolumab 3mg/kg + Ipilimumab 1mg/kg Q3W x4é€±æœŸ â†’ Nivolumabç¶­æŒ",inc:["å¾©ç™¼æ€§æ˜ç´°èƒåµå·¢ç™Œ","å…ˆå‰è‡³å°‘ä¸€ç·šåŒ–ç™‚","å…·å‚™å¯æ¸¬é‡ç—…ç¶"],exc:[],out:"ORR:24%; CBR:52%"},
{c:"Ovarian",p:["R-TX"],s:["Clear Cell Carcinoma"],n:"ATARI (ceralasertibÂ±olaparib)",ph:"ENGOT-ov58/AZ",d:"CeralasertibÂ±Olaparib",t:"o",pop:"ARID1Aé¶é»ç²¾æº–é†«ç™‚ï¼šé‡å°ARID1Açªè®ŠOCCCï¼ŒATRæŠ‘åˆ¶åŠ‘å±•ç¾ORR 14%èˆ‡è‰¯å¥½ç–¾ç—…æ§åˆ¶æ½›åŠ›(CBR 47%)ã€‚",rat:"ARID1Açªè®Šå°è‡´DNAæå‚·ä¿®å¾©å£“åŠ›å¢åŠ ï¼Œåˆ©ç”¨ATRæŠ‘åˆ¶åŠ‘(Ceralasertib)èª˜å°åˆæˆè‡´æ­»ã€‚",reg:"Cohort 1(ARID1A def): Ceralasertibå–®è—¥\nCohort 2: Ceralasertib+Olaparib",inc:["å¾©ç™¼æ€§æ˜ç´°èƒç™Œæˆ–å­å®®å…§è†œæ¨£ç™Œ","NGSè­‰å¯¦ARID1Aç¼ºå¤±/çªè®Š","é‰‘é¡è€è—¥æˆ–ä¸é©åˆå«é‰‘æ²»ç™‚"],exc:[],out:"ARID1Aç¼ºå¤±çµ„ORR:14%; CBR at 16w:47%"},
{c:"Ovarian",p:["R-TX"],s:["Clear Cell Carcinoma"],n:"DOVE",ph:"GSK",d:"Dostarlimab+Bevacizumab",t:"o",pop:"PD-1æŠ‘åˆ¶+æŠ—è¡€ç®¡æ–°ç”Ÿï¼Œå°‡å°åŒ–ç™‚ä¸æ•æ„Ÿçš„é€æ˜ç´°èƒç™Œè½‰æˆå…ç–«/å…ç–«+æŠ—è¡€ç®¡æ–°ç”Ÿæ–°ç­–ç•¥ã€‚",rat:"OCCCåˆ©ç”¨PD-1+anti-VEGFé›™é‡é˜»æ–·æ”¹å–„é«˜åº¦å…ç–«æŠ‘åˆ¶ä¹‹å¾®ç’°å¢ƒã€‚",reg:"Dostarlimab 1000mg Q6W + Bevacizumab 15mg/kg Q3W ç›´è‡³é€²å±•",inc:["å¾©ç™¼æ€§é€æ˜ç´°èƒåµå·¢ç™Œ"],exc:[],out:"æ‹›å‹Ÿä¸­(Ongoing)"},
{c:"Ovarian",p:["P-TX","R-TX"],s:["Mucinous (MOC) é‘‘å®š"],n:"mEOC / GOG-0241",ph:"NRG Oncology/GOG",d:"Pac-Carbo vs Oxal-CapeÂ±Bev",t:"p",pop:"ç½•è¦‹ç™Œåˆ¥æ¨™èªŒæ€§ç ”ç©¶ï¼šå› æ”¶æ¡ˆå›°é›£æå‰çµ‚æ­¢ï¼ŒåŸç™¼æ€§mEOCäºçµ„GIæ–¹æ¡ˆå±•ç¾è¼ƒä½³ç”Ÿå­˜ç²ç›Šè¶¨å‹¢ã€‚",rat:"ç¬¬ä¸€å€‹é‡å°mEOCçš„å¤šåœ‹éš¨æ©Ÿè©¦é©—ï¼Œå°æ¯”å©¦ç™ŒåŒ–ç™‚èˆ‡GI-typeæ–¹æ¡ˆä¸¦æ¢ç´¢Bevçš„è§’è‰²ã€‚",reg:"1. Paclitaxel+CarboplatinÂ±Bevacizumab 15mg/kg Q3W\n2. Oxaliplatin 130mg/mÂ²+Capecitabine 850mg/mÂ² bid(D1-14)Â±Bev",inc:["æ–°è¨ºæ–·FIGO Stage II-IVæˆ–Stage Iå¾©ç™¼ä¹‹åŸç™¼é»æ¶²æ€§ä¸Šçš®æ€§åµå·¢ç™Œ"],exc:[],out:"åŸç™¼æ€§mEOCäºçµ„OS HR:0.36(p=0.14); PFS HR:0.62(p=0.40)"},
{c:"Ovarian",p:["R-TX"],s:["Mucinous (MOC) é‘‘å®š"],n:"mFOLFIRINOX+Bev",ph:"Yonsei University",d:"modified FOLFIRINOX+Bevacizumab",t:"o",pop:"GI-styleæ–¹æ¡ˆå‰ç»æ¢ç´¢ï¼šé‡å°é›£æ²»å‹mEOCï¼Œé«˜å¼·åº¦ä¸‰è—¥åŒ–ç™‚è¯ç”¨æ¨™é¶ï¼Œå…‹æœå‚³çµ±åŒ–ç™‚è€è—¥æ€§ã€‚",rat:"è€ƒé‡mEOCçš„GIéºå‚³ç‰¹æ€§ï¼Œå°‡FOLFIRINOXæ–¹æ¡ˆæ‡‰ç”¨æ–¼åµå·¢ç™Œã€‚",reg:"Bev 5mg/kg+Oxaliplatin 85mg/mÂ²+Leucovorin 400mg/mÂ²+Irinotecan 150mg/mÂ²+5-FU 2400mg/mÂ²(46h) Q2W",inc:["å¾©ç™¼æˆ–è½‰ç§»æ€§åµå·¢é»æ¶²æ€§è…ºç™Œ","å…ˆå‰æ¥å—é2ç·šä»¥ä¸‹å…¨èº«æ€§æ²»ç™‚"],exc:[],out:"è©¦é©—é€²è¡Œä¸­(Ongoing)"},
{c:"Ovarian",p:["P-MT"],s:["BRCA mutation"],n:"SOLO-1",ph:"AZ",d:"Olaparib",t:"p",pop:"BRCAmä¸€ç·šç¶­æŒé‡‘æ¨™æº–ï¼š7å¹´å­˜æ´»ç‡é”67%ï¼ŒPFS HR 0.33ã€‚",rat:"é‡å°ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰è‰¯å¥½ä¹‹BRCAçªè®Šæ‚£è€…ï¼ŒPARPié”æˆåˆæˆè‡´æ­»æ•ˆæœå»¶ç·©å¾©ç™¼ã€‚",reg:"Olaparib 300mg BIDç¶­æŒï¼ˆé€šå¸¸è‡³2å¹´æˆ–é€²å±•ï¼‰\nå°ç…§çµ„: Placebo",inc:["æ–°è¨ºæ–·æ™šæœŸåµå·¢ç™Œ","germlineæˆ–somatic BRCA1/2çªè®Š","ä¸€ç·šplatinumåŒ–ç™‚å¾ŒCR/PR"],exc:["å…ˆå‰æ¥å—PARPæŠ‘åˆ¶åŠ‘","æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©"],out:"mPFS: 56.0m vs 13.8m(HR 0.30); 7yr OS Rate 67%"},
{c:"Ovarian",p:["P-MT"],s:["HRD positive (wt)","HRD negative (pHRD)"],n:"PRIMA",ph:"GSK",d:"Niraparib",t:"p",pop:"å…¨äººç¾¤ä¸€ç·šç¶­æŒï¼šHRD+ PFS HR 0.43ï¼›å…¨é«”ITT HR 0.62ï¼Œç¢ºç«‹ä¸éœ€é™ç¸®åˆ°BRCAçš„ä¸€ç·šç¶­æŒç­–ç•¥ã€‚",rat:"ä¸è«–HRDç‹€æ…‹ï¼ŒPARPiå¼·åŒ–ä¸€ç·šåŒ–ç™‚å¾Œç¶­æŒç²ç›Šï¼Œç‰¹åˆ¥é‡å°é«˜é¢¨éšªæ—ç¾¤ã€‚",reg:"Niraparibç¶­æŒï¼ˆèµ·å§‹åŠ‘é‡ä¾é«”é‡/è¡€å°æ¿èª¿æ•´ï¼›è‡³36å€‹æœˆæˆ–é€²å±•ï¼‰\nå°ç…§çµ„: Placebo",inc:["æ–°è¨ºæ–·Stage III/IVã€é«˜å¾©ç™¼é¢¨éšª","ä¸€ç·šplatinumåŒ–ç™‚å¾ŒCR/PR"],exc:["MDS/AMLé¢¨éšª","å…ˆå‰PARPæŠ‘åˆ¶åŠ‘","æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©"],out:"HRD+ PFS HR 0.43(CI 0.31-0.59); ITT HR 0.62"},
{c:"Ovarian",p:["P-MT"],s:["HRD positive (wt)"],n:"PAOLA-1",ph:"AZ",d:"Olaparib+Bevacizumab",t:"p",pop:"Olaparib+Bevç¶­æŒå…¨é«”PFS HR 0.59ï¼ŒHRD+æ—ç¾¤æ•ˆç›Šæ›´å¤§ï¼ˆHR 0.33ï¼‰ã€‚HRD+5å¹´OSç‡75.2%ã€‚",rat:"çµåˆanti-VEGF(Bev)é‡å¡‘è¡€ç®¡ç’°å¢ƒèˆ‡PARPi(Ola)æŠ‘åˆ¶DNAä¿®å¾©ä¹‹é›™é‡æ©Ÿè½‰ã€‚",reg:"æ‰€æœ‰æ‚£è€…å…ˆæ¥å—å«Bevä¸€ç·šåŒ–ç™‚\nArm A: Olaparib+Bevacizumabç¶­æŒ\nArm B: Bevacizumabç¶­æŒï¼ˆå°ç…§ï¼‰",inc:["æ–°è¨ºæ–·Stage III/IVã€é«˜å¾©ç™¼é¢¨éšª","åŒ–ç™‚+Bevå¾ŒCR/PR","åˆ†å±¤HRD/BRCA"],exc:["ä¸é©åˆBevï¼ˆå‡ºè¡€/å»”ç®¡/è¡€æ “é¢¨éšªï¼‰","å…ˆå‰PARPæŠ‘åˆ¶åŠ‘"],out:"HRD+ 5yr OS: 75.2% vs 58.3%(HR 0.62)"},
{c:"Ovarian",p:["P-MT"],s:["BRCA mutation","HRD positive (wt)"],n:"ATHENA-MONO",ph:"Clovis",d:"Rucaparib",t:"p",pop:"Rucaparibä¸€ç·šç¶­æŒæ”¹å–„PFSï¼ˆITTï¼šHR 0.52ï¼›HRDï¼šHR 0.47ï¼›HRD-negativeï¼šHR 0.65ï¼‰ã€‚",rat:"è­‰å¯¦Rucaparibåœ¨ä¸€ç·šå«é‰‘åŒ–ç™‚åæ‡‰å¾Œçš„å–®è—¥ç¶­æŒåƒ¹å€¼ï¼Œä¸è«–HRDç‹€æ…‹ã€‚",reg:"Rucaparibç¶­æŒï¼ˆè‡³é€²å±•ï¼‰\nå°ç…§çµ„: Placebo",inc:["æ–°è¨ºæ–·æ™šæœŸï¼ˆå¤šç‚ºIII/IVï¼‰","ä¸€ç·šplatinumå¾ŒCR/PR","æ¶µè“‹HRD/HRP"],exc:["è‚åŠŸèƒ½ç•°å¸¸","å…ˆå‰PARPæŠ‘åˆ¶åŠ‘","æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©"],out:"ITT PFS: 28.7m vs 11.3m(HR 0.52)"},
{c:"Ovarian",p:["P-MT"],s:["HRD positive (wt)","HRD negative (pHRD)"],n:"DUO-O (ENGOT-OV46)",ph:"AstraZeneca",d:"Durvalumab+Olaparib+Bev",t:"p",pop:"ä¸€ç·šåˆä½µå…ç–«/æŠ—è¡€ç®¡/PARPiï¼šHRD+ä¸‰è—¥çµ„PFS HR 0.49; ITT HR 0.63ã€‚",rat:"IO+PARPi+anti-VEGFä¸‰è—¥è¯ç”¨ï¼Œæ–¼ä¸€ç·šåæ‡‰å¾Œæ¸…é™¤å¾®å°æ®˜ç•™ç—…ç¶ä¸¦å»¶ç·©å¾©ç™¼ã€‚",reg:"Backbone: Carbo/Pacli+Bev\nArm 3: Bev+Durvalumab+Olaparib 300mg bidç¶­æŒè‡³PD",inc:["æ–°è¨ºæ–·FIGO III-IVæœŸä¸Šçš®æ€§åµå·¢ç™Œ","æ¥å—PDSæˆ–IDSä¸”å°é‰‘é¡æœ‰åæ‡‰","non-tBRCAmï¼ˆä»¥HRD/ITTç‚ºä¸»è¦åˆ†æï¼‰"],exc:["ä¸é©åˆBev","æ—¢å¾€å…ç–«æ²»ç™‚/PARP"],out:"HRD+(non-BRCAm) PFS HR 0.49(CI 0.34-0.69); ITT HR 0.63"},
{c:"Ovarian",p:["P-MT"],s:["BRCA mutation","HRD positive (wt)"],n:"DS8201-772 (Enhertu/T-DXd)",ph:"AstraZeneca",d:"T-DXdç¶­æŒ",t:"o",pop:"HER2-ADCä¸€ç·šç¶­æŒï¼šç„æº–HER2è¡¨ç¾åµå·¢ç™Œäºç¾¤ç¼ºä¹æ˜ç¢ºæ¨™é¶ç¶­æŒæ¨™æº–ã€ä»æ˜“å¾©ç™¼çš„unmet needã€‚",rat:"æ¨™é¶HER2 ADCç”¨æ–¼ç¶­æŒã€‚T-DXdæ¥µé«˜DAR(8)å„ªå‹¢æ¸…é™¤åŒ–ç™‚å¾Œæ®˜é¤˜HER2è¡¨ç¾å¾®å°ç—…ç¶ã€‚",reg:"Trastuzumab deruxtecan 5.4mg/kg IV Q3Wç¶­æŒè‡³é€²å±•",inc:["æ–°è¨ºæ–·æ™šæœŸåµå·¢ç™ŒHER2è¡¨ç¾è€…","ä¸€ç·šåŒ–ç™‚å¾Œé”CR/PR"],exc:[],out:"æ‹›å‹Ÿä¸­(Ongoing)"},
{c:"Ovarian",p:["R-MT"],s:["PARPi Maint"],n:"NOVA",ph:"GSK",d:"Niraparib",t:"p",pop:"å¾©ç™¼é‰‘æ•æ„ŸNiraparibç¶­æŒé¡¯è‘—å»¶é•·PFSï¼ˆgBRCAï¼šHR 0.27ï¼›non-gBRCAï¼šHR 0.45ï¼‰ã€‚",rat:"é¦–å€‹è­‰æ˜PARPiåœ¨PSOCæ‚£è€…ä¸­ä¸è«–BRCAæ˜¯å¦çªè®Šçš†æœ‰ç²ç›Šçš„ç ”ç©¶ã€‚",reg:"Niraparibç¶­æŒï¼ˆè‡³é€²å±•ï¼‰\nå°ç…§çµ„: Placebo\nåˆ†gBRCAèˆ‡non-gBRCA cohort",inc:["Platinum-sensitive recurrent ovarian cancer","å°æœ€è¿‘ä¸€æ¬¡platinumæœ‰åæ‡‰"],exc:["MDS/AMLé¢¨éšª","å…ˆå‰PARPæŠ‘åˆ¶åŠ‘"],out:"gBRCAm mPFS: 21.0m vs 5.5m(HR 0.27); non-gBRCA HR 0.45"},
{c:"Ovarian",p:["R-MT"],s:["PARPi Maint"],n:"ARIEL3",ph:"Clovis",d:"Rucaparib",t:"p",pop:"Rucaparibç¶­æŒæ”¹å–„PFSï¼ˆITTï¼šHR 0.36ï¼›BRCAçªè®Šï¼šHR 0.23ï¼‰ã€‚ç²¾ç¢ºåˆ†æµç¶­æŒç²ç›Šï¼šBRCAm HR 0.23ï¼›HRD+ HR 0.32ã€‚",rat:"åˆ©ç”¨LOHï¼ˆé›œåˆæ€§ä¸Ÿå¤±ï¼‰æª¢æ¸¬è¼”åŠ©åˆ¤å®šHRDç‹€æ…‹ï¼Œå°èˆªPARPiåœ¨å¾©ç™¼éšæ®µçš„ä½¿ç”¨ã€‚",reg:"Rucaparibç¶­æŒï¼ˆè‡³é€²å±•ï¼‰\nå°ç…§çµ„: Placebo",inc:["Platinum-sensitive recurrent ovarian cancer","å°platinumæœ‰åæ‡‰","åˆ†å±¤BRCA-mut/HRD/ITT"],exc:["å…ˆå‰PARPæŠ‘åˆ¶åŠ‘","æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©"],out:"BRCAm mPFS: 16.6m vs 5.4m(HR 0.23); HRD HR~0.32; ITT HR~0.36"},
{c:"Ovarian",p:["R-MT"],s:["PARPi Maint"],n:"SOLO2",ph:"AZ",d:"Olaparib",t:"p",pop:"Olaparibç¶­æŒå»¶é•·PFS(HR 0.30)ï¼ŒBRCAmæ—ç¾¤mOSé¡¯è‘—å»¶é•·è‡³51.7m(HR 0.74)ã€‚",rat:"ç¢ºèªOlaparibåœ¨å¾©ç™¼ç¶­æŒéšæ®µèƒ½å°‡PFSç²ç›Šè½‰åŒ–ç‚ºæœ€çµ‚OSç²ç›Šã€‚",reg:"Olaparib tabletsç¶­æŒï¼ˆè‡³é€²å±•ï¼‰\nå°ç…§çµ„: Placebo",inc:["Platinum-sensitive recurrent ovarian cancer","å°platinumæœ‰åæ‡‰","BRCA1/2 mutation"],exc:["å…ˆå‰PARPæŠ‘åˆ¶åŠ‘","æŒçºŒæ€§éª¨é«“æŠ‘åˆ¶æœªæ¢å¾©"],out:"mOS: 51.7m vs 38.8m(HR 0.74); PFS HR~0.30; median OS +12.9 months"},
// CERVICAL
{c:"Cervical",p:["P-TX"],s:["Locally Advanced (CCRT)"],n:"KEYNOTE-A18 (ENGOT-cx11)",ph:"MSD",d:"Pembrolizumab+CCRT",t:"p",pop:"LACCæ¨™æº–ï¼š36m OS 82.6%(HR 0.67)ã€‚å…ç–«æ²»ç™‚æ•´åˆå…¥æ ¹æ²»åŒæ­¥åŒ–æ”¾ç™‚å ´æ™¯çš„é‡Œç¨‹ç¢‘ã€‚",rat:"å°‡å…ç–«æ•´åˆå…¥é«˜é¢¨éšªå±€éƒ¨æ™šæœŸä¹‹æ ¹æ²»åŒæ­¥åŒ–æ”¾ç™‚ã€‚",reg:"Arm A: CCRT(Cisplatin 40mg/mÂ² é€±æœ+RT 45-50.4Gy)+Pembro 200mg Q3W x5é€±æœŸ\nâ†’ ç¶­æŒPembro 400mg Q6W x15é€±æœŸ\nArm B: CCRT+Placebo",inc:["æ–°è¨ºæ–·Stage IB2-IIB LN(+)æˆ–Stage III-IVAå±€éƒ¨æ™šæœŸ"],exc:["æ—¢å¾€ç³»çµ±æ€§æ²»ç™‚/å…ç–«æ²»ç™‚","æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚","ä¸å¯æ§æ„ŸæŸ“","æ”¾ç™‚ç¦å¿Œ"],out:"24m PFS:68% vs 57%(HR 0.70); 36m OS:82.6% vs 74.8%(HR 0.67)"},
{c:"Cervical",p:["P-TX"],s:["Locally Advanced (CCRT)"],n:"INTERLACE",ph:"UCL",d:"Induction Carbo/Pacli x6 â†’ CCRT",t:"p",pop:"èª˜å°åŒ–ç™‚â†’CCRTç­–ç•¥ï¼š5å¹´OS 80% vs 72%(HR 0.60)ã€‚æ²»ç™‚åºåˆ—æœ¬èº«å¸¶ä¾†å­˜æ´»å¢ç›Šã€‚",rat:"åˆ©ç”¨èª˜å°åŒ–ç™‚(Induction Chemo)è§£æ±ºæ”¾ç™‚å‰çš„å¾®å°è½‰ç§»ã€‚",reg:"Arm A: èª˜å°æœŸPaclitaxel 80mg/mÂ²+Carboplatin AUC2 æ¯é€± x6é€±æœŸ â†’ æ¥çºŒæ¨™æº–CCRT(Cisplatin+RT)\nArm B: æ¨™æº–CCRT alone",inc:["Treatment-naÃ¯ve locally advanced cervical cancer","é©åˆæ ¹æ²»æ€§CCRT"],exc:["ç„¡æ³•æ¥å—åŒ–ç™‚æˆ–æ ¹æ²»æ€§æ”¾ç™‚","é‡å¤§å…±ç—…/æ„ŸæŸ“","æ‡·å­•"],out:"5yr OS:80% vs 72%(HR 0.60); 5yr PFS:73% vs 64%(HR 0.65)"},
{c:"Cervical",p:["P-TX"],s:["Locally Advanced (CCRT)"],n:"CALLA",ph:"AZ",d:"Durvalumab+CCRT",t:"p",pop:"æ•´é«”è©¦é©—çµæœç‚ºé™°æ€§ã€‚å±€éƒ¨æ™šæœŸå®®é ¸ç™Œä¸­CCRTåŠ å…¥Durvalumabä¸¦æœªé¡¯è‘—æ”¹å–„PFS(HR 0.84; P=0.174)ã€‚",rat:"æ¢ç´¢PD-L1æŠ‘åˆ¶åŠ‘èˆ‡CCRTè¯ç”¨æ˜¯å¦èƒ½ç”¢ç”Ÿå”åŒå…ç–«æ•ˆæ‡‰ã€‚",reg:"Arm A: Durvalumab+CCRT â†’ æŒçºŒDurvalumab\nArm B: Placebo+CCRT â†’ æŒçºŒPlacebo",inc:["Untreated locally advanced cervical cancerï¼Œæ¥å—æ ¹æ²»æ€§CCRT"],exc:["æ—¢å¾€å…ç–«æ²»ç™‚","æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚","æ”¾ç™‚/åŒ–ç™‚ç¦å¿Œ"],out:"PFS HR 0.84(CI 0.65-1.08)ï¼Œæœªé”é¡¯è‘—"},
{c:"Cervical",p:["P-TX"],s:["Locally Advanced (CCRT)"],n:"OUTBACK (ANZGOG 0902)",ph:"GOG/ANZGOG",d:"CCRT+Adjuvant Chemo",t:"p",pop:"è¼”åŠ©åŒ–ç™‚è² å‘çµè«–ï¼šCCRTå¾Œé¡å¤–å¢åŠ 4é€±æœŸè¼”åŠ©åŒ–ç™‚ä¸¦æœªæ”¹å–„5å¹´OSæˆ–PFS(HR 0.91)ã€‚",rat:"é©—è­‰CCRTå®Œæˆå¾ŒåŠ å…¥å…¨èº«æ€§åŒ–ç™‚æ˜¯å¦èƒ½é€²ä¸€æ­¥æ¸…é™¤é ç«¯è½‰ç§»ã€‚",reg:"æ¨™æº–CCRTçµæŸå¾Œæ¥çºŒCarboplatin/Paclitaxel Q3W x4é€±æœŸ",inc:["Stage IB2-IVAå±€éƒ¨æ™šæœŸå®®é ¸ç™Œ"],exc:[],out:"5yr OS:72% vs 71%; PFS HR:0.91(P=0.61)"},
{c:"Cervical",p:["P-TX"],s:["Locally Advanced (NIC)"],n:"NACI Study",ph:"Henlius",d:"Camrelizumab+NACT",t:"p",pop:"æ–°è¼”åŠ©å…ç–«å¼·æ•ˆæ‡‰ï¼šLACC pCRç‡é«˜é”38.6%ï¼Œé¡¯è‘—å„ªæ–¼å‚³çµ±æ–°è¼”åŠ©åŒ–ç™‚ã€‚",rat:"PD-1æŠ‘åˆ¶åŠ‘èˆ‡åŒ–ç™‚è¯ç”¨ä½œç‚ºæ‰‹è¡“å‰å‰å°æ²»ç™‚ï¼Œç¸®å°è…«ç˜¤é«”ç©ä¸¦æ¸…é™¤å¾®å°è½‰ç§»ç—…ç¶ã€‚",reg:"Camrelizumab 200mg+Cisplatin/Paclitaxel Q3W x2-3é€±æœŸ â†’ æ ¹æ²»æ€§æ‰‹è¡“",inc:["Stage IB3, IIA2, IIB(FIGO 2018) å±€éƒ¨æ™šæœŸå®®é ¸ç™Œ","ECOG 0-1","æœªæ›¾æ¥å—éåŒ–æ”¾ç™‚"],exc:[],out:"pCR Rate:38.6%; ORR:97.7%"},
{c:"Cervical",p:["P-TX"],s:["Locally Advanced (NIC)"],n:"NATIC Trial",ph:"BeiGene/SYSU",d:"Tislelizumab+NACT",t:"p",pop:"æ–°è¼”åŠ©å…ç–«æ–°é¸æ“‡ï¼šTislelizumabè¯ç”¨åŒ–ç™‚é”æˆ41%çš„pCRç‡ï¼Œå±•ç¾å¼·å¤§çš„è¡“å‰è…«ç˜¤é™éšèƒ½åŠ›ã€‚",rat:"æ¢ç´¢PD-1æŠ‘åˆ¶åŠ‘Tislelizumabåœ¨å±€éƒ¨æ™šæœŸæ‚£è€…æ‰‹è¡“å‰çš„æ‡‰ç”¨ã€‚",reg:"Tislelizumab 200mg+Paclitaxel/Cisplatin Q3W x3é€±æœŸ â†’ å»£æ³›æ€§å­å®®åˆ‡é™¤è¡“",inc:["FIGO 2018 Stage IB3-IIBå±€éƒ¨æ™šæœŸé±—ç™Œ/è…ºç™Œ/è…ºé±—ç™Œ","ECOG 0-1"],exc:[],out:"pCR Rate:41%; ORR:94.7%; Gradeâ‰¥3 TRAEç‡ç´„25.6%"},
{c:"Cervical",p:["P-TX"],s:["Locally Advanced (NIC)"],n:"Cadonilimab+NACT â†’ Surgery",ph:"Akeso",d:"Cadonilimab(PD-1/CTLA-4)+NACT",t:"o",pop:"é›™ç‰¹ç•°æ€§æŠ—é«”é ˜èˆªï¼šPD-1/CTLA-4é›™ç‰¹ç•°æ€§æŠ—é«”è¯ç”¨åŒ–ç™‚ä½œç‚ºæ–°è¼”åŠ©æ²»ç™‚ï¼Œå±•ç¾æ¯”å–®å…ç–«æ›´é«˜çš„è‡¨åºŠç²ç›Šæ½›åŠ›ã€‚",rat:"åˆ©ç”¨é›™é¶é»é˜»æ–·æ©Ÿåˆ¶å¼·åŒ–è…«ç˜¤å¾®ç’°å¢ƒçš„å…ç–«æ´»åŒ–ã€‚",reg:"Cadonilimab 10mg/kg+Carboplatin/Paclitaxel Q3W x3é€±æœŸ â†’ æ‰‹è¡“æˆ–æ”¾ç™‚",inc:["æ–°è¨ºæ–·FIGO Stage IB3-IIA2ï¼ˆå«å·¨å¤§è…«ç˜¤ï¼‰æˆ–IIB-IVAæœŸ"],exc:[],out:"åˆæ­¥ORRè¡¨ç¾å„ªç•°ï¼Œç—…ç†ç·©è§£æ•¸æ“šè¿½è¹¤ä¸­(Ongoing)"},
{c:"Cervical",p:["P-TX"],s:["Early Stage (Surgery)"],n:"LACC Trial",ph:"NEJM/Academic",d:"Open vs MIS Radical Hysterectomy",t:"p",pop:"æ‰‹è¡“é»ƒé‡‘æº–å‰‡ï¼šMISç›¸è¼ƒå‚³çµ±é–‹è…¹æ‰‹è¡“ï¼Œå¾©ç™¼é¢¨éšªé¡¯è‘—è¼ƒé«˜ä¸”3å¹´å­˜æ´»ç‡è¼ƒä½ã€‚",rat:"è©•ä¼°é”æ–‡è¥¿æˆ–è…¹è…”é¡å¾®å‰µæ‰‹è¡“æ˜¯å¦èƒ½é”æˆèˆ‡é–‹è…¹æ‰‹è¡“åŒç­‰çš„è…«ç˜¤å­¸é å¾Œã€‚",reg:"å°ç…§çµ„: å‚³çµ±é–‹è…¹æ ¹æ²»æ€§å­å®®åˆ‡é™¤è¡“(Open RH)\nè©¦é©—çµ„: å¾®å‰µæ ¹æ²»æ€§å­å®®åˆ‡é™¤è¡“(MIS RH)",inc:["FIGO 2009 Stage IA1(æœ‰LVSI), IA2, æˆ–IB1å®®é ¸ç™Œ","çµ„ç¹”å­¸ç‚ºé±—ç™Œ/è…ºç™Œ/è…ºé±—ç™Œ","ECOG 0-1"],exc:["è…«ç˜¤ç›´å¾‘>4cm","å·²çŸ¥æ·‹å·´çµè½‰ç§»æˆ–é ç«¯è½‰ç§»"],out:"3yr DFS:91.2%(MIS) vs 97.1%(Open); HR for recurrence 3.74(P=0.002)"},
{c:"Cervical",p:["P-TX"],s:["Early Stage (Surgery)"],n:"SHAPE Trial (CCTG CX.5)",ph:"CCTG/Academic",d:"Simple vs Radical Hysterectomy",t:"p",pop:"ä½é¢¨éšªæ‰‹è¡“é™éšï¼šä½é¢¨éšªæ—©æœŸæ‚£è€…ï¼ŒSimpleåˆ‡é™¤çš„3å¹´ç›†è…”å¾©ç™¼ç‡ä¸åŠ£æ–¼Radicalåˆ‡é™¤ã€‚",rat:"æ¢è¨ä½é¢¨éšªæ—©æœŸæ‚£è€…æ˜¯å¦èƒ½é€éæ¸›å°‘åˆ‡é™¤ç¯„åœé™ä½è¡“å¾Œä½µç™¼ç—‡ä¸¦ç¶­æŒç”Ÿå­˜ç‡ã€‚",reg:"å°ç…§çµ„: å»£æ³›æ€§å­å®®åˆ‡é™¤(Radical RH)+ç›†è…”æ·‹å·´æ¸…æƒ\nè©¦é©—çµ„: å–®ç´”å­å®®åˆ‡é™¤(Simple RH)+ç›†è…”æ·‹å·´æ¸…æƒ",inc:["FIGO 2018 Stage IA2æˆ–IB1(â‰¤2cm)","é–“è³ªæµ¸æ½¤æ·±åº¦<10mm","Grade 1-3é±—ç™Œ/è…ºç™Œ/è…ºé±—ç™Œ"],exc:["å½±åƒå­¸æ‡·ç–‘æ·‹å·´çµè½‰ç§»","å°ç´°èƒç¥ç¶“å…§åˆ†æ³Œç™Œ"],out:"3yr Pelvic Recurrence:2.52%(Simple) vs 2.17%(Radical); ç¬¦åˆéåŠ£æ•ˆæ€§"},
{c:"Cervical",p:["P-MT"],s:["Maintenance"],n:"KEYNOTE-826",ph:"MSD",d:"Pembrolizumab+ChemoÂ±Bev",t:"p",pop:"ä¸€ç·šR/Må®®é ¸ç™Œé»ƒé‡‘æ¨™æº–ï¼šåŒ–ç™‚åŸºç¤ä¸ŠåŠ å…ç–«æ²»ç™‚é¡¯è‘—æ”¹å–„OS(HR 0.63)ã€‚å®Œæˆèª˜å°å¾Œæ¥çºŒå…ç–«ç¶­æŒç›´è‡³PDæˆ–æ»¿24å€‹æœˆã€‚",rat:"ICIèˆ‡åŒ–ç™‚å”åŒæ•ˆæ‡‰ï¼Œå¾ŒçºŒå–®è—¥å…ç–«ç¶­æŒæŒçºŒæ´»åŒ–å…ç–«ç³»çµ±ä»¥æ§åˆ¶è…«ç˜¤é€²å±•ã€‚",reg:"Arm 1: Pembrolizumab 200mg Q3W+Chemo(Pacli+Cis/Carbo)Â±Bev 15mg/kg Q3W\nArm 2: Placebo+ChemoÂ±Bev",inc:["Persistent/recurrent/metastaticå®®é ¸ç™Œ","1L systemic therapy","ä¸»è¦åˆ†æä»¥PD-L1 CPSåˆ†å±¤"],exc:["æ—¢å¾€å…ç–«æ²»ç™‚","æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚"],out:"CPSâ‰¥1æ—ç¾¤mOS:28.6m vs 16.5m(HR 0.60); ITT OS HR 0.63"},
{c:"Cervical",p:["R-TX"],s:["Recurr / Metastatic"],n:"GOG-240",ph:"NCI/GOG",d:"Chemo+Bevacizumab",t:"p",pop:"è½‰ç§»æ€§å®®é ¸ç™Œé‡Œç¨‹ç¢‘ï¼šé¦–å€‹è­‰æ˜åŠ å…¥Bevèƒ½é¡¯è‘—å»¶é•·OS(16.8m vs 13.3m, HR 0.71)çš„ç ”ç©¶ã€‚",rat:"æŠ—è¡€ç®¡æ–°ç”Ÿè—¥ç‰©å”åŒé›™æ¨™é¶åŒ–ç™‚ï¼Œå¼·åŒ–å°æ™šæœŸå®®é ¸ç™Œçš„ç³»çµ±æ€§æ§åˆ¶ã€‚",reg:"Cisplatin+Paclitaxelï¼ˆæˆ–Topotecan+Paclitaxelï¼‰+Bevacizumab 15mg/kg Q3W",inc:["å¾©ç™¼ã€æŒä¹…æ€§æˆ–è½‰ç§»æ€§å®®é ¸ç™Œ","å…ˆå‰æœªæ¥å—éé‡å°R/Mä¹‹åŒ–ç™‚","ECOG 0-1"],exc:["è‡¨åºŠé¡¯è‘—ä¹‹å¿ƒè¡€ç®¡ç–¾ç—…","æ›¾å—éå…¨èº«æ€§è¡€ç®¡æŠ‘åˆ¶åŠ‘æ²»ç™‚"],out:"mOS:16.8m vs 13.3m(HR 0.71, P=0.004)"},
{c:"Cervical",p:["R-TX"],s:["Recurr / Metastatic"],n:"BEATcc",ph:"Roche",d:"Atezolizumab+Chemo+Bev",t:"p",pop:"ä¸€ç·šR/Må®®é ¸ç™Œï¼šåŠ å…¥Atezolizumabé¡¯è‘—å»¶é•·PFS(13.7m vs 10.4m)èˆ‡OS(32.1m vs 22.8m)ã€‚PFS HR 0.62ï¼›OS HR 0.68ã€‚",rat:"PD-L1é˜»æ–·+VEGFæŠ‘åˆ¶åŠ‘+åŒ–ç™‚ï¼Œä¸‰è»Œè¯ç”¨å¼·åŒ–è…«ç˜¤å¾®ç’°å¢ƒä¹‹æ®ºå‚·åŠ›ã€‚",reg:"Arm A: Atezolizumab+Bev+platinum chemo â†’ Atezolizumab+Bevç¶­æŒ\nArm B: Bev+platinum chemo â†’ Bevç¶­æŒ",inc:["Untreated metastatic/persistent/recurrentå®®é ¸ç™Œ","å¯æ¥å—å«Bevçš„æ¨™æº–ä¸€ç·š"],exc:["æ—¢å¾€å…ç–«æ²»ç™‚","æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚","ä¸é©åˆBev"],out:"mPFS HR 0.62; mOS HR 0.68(CI 0.52-0.88)"},
{c:"Cervical",p:["R-TX"],s:["Recurr / Metastatic"],n:"innovaTV 301 (ENGOT-cx12)",ph:"Genmab",d:"Tisotumab Vedotin(ADC)",t:"p",pop:"å¾Œç·šADCçªç ´ï¼šTisotumab vedotinç›¸è¼ƒé†«å¸«é¸æ“‡åŒ–ç™‚æ”¹å–„OS(HR 0.70)ã€‚ORR 17.8%ã€‚",rat:"æ¨™é¶çµ„ç¹”å› å­(Tissue Factor) ADCï¼Œè§£æ±ºå¾Œç·šåŒ–ç™‚è€è—¥ã€‚",reg:"Arm A: Tisotumab Vedotin 2.0mg/kg IV Q3W\nArm B: é†«å¸«é¸æ“‡åŒ–ç™‚(Chemo SoC)",inc:["Recurrent/metastaticå®®é ¸ç™Œ","2L/3Læ²»ç™‚æƒ…å¢ƒ"],exc:["ä¸é©åˆADC/æ—¢å¾€ç›¸é—œè—¥ç‰©é™åˆ¶","åš´é‡è§’è†œ/çœ¼éƒ¨é¢¨éšª"],out:"mOS:11.5m vs 9.5m(HR 0.70); ORR 17.8% vs 5.2%"},
{c:"Cervical",p:["R-TX"],s:["Recurr / Metastatic"],n:"EMPOWER-Cervical 1",ph:"Regeneron",d:"Cemiplimab å–®è—¥",t:"p",pop:"äºŒç·šå¾Œå–®è—¥å…ç–«æ²»ç™‚ï¼šç›¸è¼ƒåŒ–ç™‚é¡¯è‘—å»¶é•·OS(mOS 12.0m vs 8.5m; HR 0.69)ï¼Œä¸è«–çµ„ç¹”å‹æ…‹å‡æœ‰ç²ç›Šã€‚",rat:"é‡å°ä¸€ç·šé‰‘é¡åŒ–ç™‚å¤±æ•—å¾Œä¹‹æ‚£è€…ï¼ŒPD-1é˜»æ–·æä¾›æŒä¹…ç·©è§£èˆ‡ç”Ÿå­˜å„ªå‹¢ã€‚",reg:"Arm A: Cemiplimab\nArm B: é†«å¸«é¸æ“‡å–®è—¥åŒ–ç™‚",inc:["Recurrent/metastaticå®®é ¸ç™Œ","Progressed after 1L platinum"],exc:["æ—¢å¾€å…ç–«æ²»ç™‚","æ´»å‹•æ€§è‡ªé«”å…ç–«éœ€æ²»ç™‚"],out:"ITT OS HR 0.69(CI 0.56-0.84)"},
// UTERINE SARCOMA
{c:"Uterine Sarcoma",p:["P-TX"],s:["Primary Sarcoma"],n:"GOG-0277",ph:"GOG/NCI",d:"Gem/Doce vs Observation",t:"p",pop:"é«˜æƒ¡æ€§åº¦LMSè¼”åŠ©æ²»ç™‚ï¼šGem+Doceè¼”åŠ©åŒ–ç™‚ç›¸è¼ƒè§€å¯Ÿçµ„ï¼Œæœ‰PFSç²ç›Šè¶¨å‹¢ä½†æœªé”é¡¯è‘—å·®ç•°ã€‚",rat:"é‡å°å®Œå…¨åˆ‡é™¤çš„é«˜æƒ¡æ€§åº¦uLMSï¼Œæ¢è¨è¼”åŠ©åŒ–ç™‚æ˜¯å¦èƒ½é™ä½æ¥µé«˜å¾©ç™¼ç‡ã€‚",reg:"Gemcitabine 900mg/mÂ²(D1,D8)+Docetaxel 75mg/mÂ²(D8) Q21d x4é€±æœŸ",inc:["å®Œå…¨åˆ‡é™¤ä¹‹Stage Iå­å®®å¹³æ»‘è‚Œè‚‰ç˜¤(uLMS)","ECOG 0-1"],exc:[],out:"ç”±æ–¼æ”¶æ¡ˆå›°é›£æå‰çµ‚æ­¢ï¼Œæœªé”é¡¯è‘—çµ±è¨ˆå­¸å·®ç•°"},
{c:"Uterine Sarcoma",p:["P-TX"],s:["Primary Sarcoma"],n:"EORTC 55874",ph:"EORTC",d:"Adjuvant Radiotherapy",t:"p",pop:"è¡“å¾Œæ”¾ç™‚åƒ¹å€¼ï¼šæ—©æœŸå­å®®è‚‰ç˜¤è¼”åŠ©éª¨ç›†æ”¾ç™‚èƒ½é™ä½å±€éƒ¨å¾©ç™¼ç‡ï¼Œä½†ç„¡æ³•æ”¹å–„PFSèˆ‡OSã€‚",rat:"æ¢è¨Stage I/IIå­å®®è‚‰ç˜¤æ‚£è€…è¡“å¾Œæ¥å—EBRTçš„è‡¨åºŠç²ç›Šã€‚",reg:"éª¨ç›†è…”EBRTï¼Œç¸½åŠ‘é‡50.4Gyåˆ†28æ¬¡ç…§å°„",inc:["Stage I/IIå­å®®LMSæˆ–å­å®®è‚‰ç˜¤","æ‰‹è¡“å®Œå…¨åˆ‡é™¤å¾Œ"],exc:[],out:"å±€éƒ¨å¾©ç™¼ç‡é™ä½ï¼›OS HR 0.94(P=0.69)ç„¡é¡¯è‘—å·®ç•°"},
{c:"Uterine Sarcoma",p:["P-TX"],s:["Primary Sarcoma"],n:"EORTC 62012",ph:"EORTC",d:"Doxorubicin+Ifosfamide",t:"p",pop:"æ™šæœŸä¸€ç·šçµ„åˆï¼šè¯ç”¨æ–¹æ¡ˆé¡¯è‘—æå‡ORR(26%)èˆ‡PFSï¼Œä½†OSä¸Šèˆ‡å–®è—¥Doxç›¸æ¯”ç„¡é¡¯è‘—å·®ç•°ã€‚",rat:"ä¸å¯åˆ‡é™¤æˆ–è½‰ç§»æ€§è‚‰ç˜¤ï¼Œæ¯”è¼ƒåŠ å¼·å‹è¯ç”¨åŒ–ç™‚èˆ‡å–®è—¥åŒ–ç™‚çš„ç™‚æ•ˆæ¬Šè¡¡ã€‚",reg:"Doxorubicin 75mg/mÂ²+Ifosfamide 5g/mÂ²+Mesna Q3W",inc:["æ™šæœŸ/è½‰ç§»æ€§è»Ÿçµ„ç¹”è‚‰ç˜¤ï¼ˆå«å­å®®è‚‰ç˜¤ï¼‰","å…ˆå‰æœªæ¥å—éç³»çµ±åŒ–ç™‚"],exc:[],out:"mPFS:7.4m vs 4.6m(HR 0.74); ORR:26% vs 14%"},
{c:"Uterine Sarcoma",p:["P-TX"],s:["Primary Sarcoma"],n:"GeDDiS (Phase III)",ph:"CRUK",d:"Gem/Doce vs Doxorubicin",t:"p",pop:"ä¸€ç·šæ¨™æº–å°ç…§ï¼šGem/Doceèˆ‡Doxorubicinä½œç‚ºä¸€ç·šæ²»ç™‚ï¼ŒPFSç„¡é¡¯è‘—å·®ç•°ï¼ŒDoxå…·å‚™æ›´ä½³çš„ç”¨è—¥ä¾¿åˆ©æ€§ã€‚",rat:"ç¢ºå®šGem/Doceæ˜¯å¦èƒ½å–ä»£Doxorubicinæˆç‚ºæ™šæœŸè‚‰ç˜¤ä¸€ç·šé¦–é¸ã€‚",reg:"Gemcitabine 675mg/mÂ²(D1,D8)+Docetaxel 75mg/mÂ²(D8) vs Doxorubicin 75mg/mÂ²(D1) Q3W",inc:["ä¸å¯åˆ‡é™¤æˆ–è½‰ç§»æ€§è»Ÿçµ„ç¹”è‚‰ç˜¤","ECOG 0-1"],exc:[],out:"mPFS:23.3é€±(Gem/Doce) vs 23.3é€±(Dox), HR 1.14(P=0.06)"},
{c:"Uterine Sarcoma",p:["P-TX"],s:["Primary Sarcoma"],n:"LMS-04 (Phase III)",ph:"French Sarcoma Group",d:"Doxorubicin+Trabectedin",t:"p",pop:"LMSä¸€ç·šæ–°é«˜åº¦ï¼šè¯ç”¨Trabectediné¡¯è‘—å»¶é•·å­å®®LMSä¸­ä½PFSé”å…©å€(12.2m vs 6.2m)ã€‚",rat:"å°ˆå°LMSï¼ŒDoxorubicinè¯ç”¨TrabectedinæŒ‘æˆ°å‚³çµ±å–®è—¥æ²»ç™‚ç“¶é ¸ã€‚",reg:"Doxorubicin 60mg/mÂ²+Trabectedin 1.1mg/mÂ² Q3W â†’ æ¥çºŒTrabectedinå–®è—¥ç¶­æŒ",inc:["æ™šæœŸ/è½‰ç§»æ€§å­å®®æˆ–éå­å®®LMS","ä¸€ç·šæ²»ç™‚"],exc:[],out:"mPFS:12.2m vs 6.2m(HR 0.37); mOS:31.6m vs 24.1m"},
{c:"Uterine Sarcoma",p:["P-TX","R-TX"],s:["Carcinosarcoma"],n:"NRG/GOG-0261 (Phase III)",ph:"NRG Oncology",d:"Paclitaxel+Carboplatin",t:"p",pop:"UCSæ–°æ¨™æº–ï¼šPCæ–¹æ¡ˆä¸åŠ£æ–¼Pacli/Ifoä¸”æ¯’æ€§é¡¯è‘—é™ä½ã€‚PFS 14.6m vs 10.3mã€‚",rat:"ç¢ºå®šPacli/Carbo(PC)æ˜¯å¦èƒ½å–ä»£æ¯’æ€§è¼ƒå¤§çš„Ifosfamideæ–¹æ¡ˆï¼Œæˆç‚ºç™Œè‚‰ç˜¤ä¸€ç·šæ²»ç™‚æ–°æ¨™ç«¿ã€‚",reg:"Arm A: Paclitaxel 175mg/mÂ²+Carboplatin AUC6 Q3W\nArm B: Paclitaxel 135mg/mÂ²+Ifosfamide 1.6g/mÂ²(D1-3) Q3W",inc:["æ–°è¨ºæ–·Stage III-IVæˆ–å¾©ç™¼æ€§å­å®®/åµå·¢ç™Œè‚‰ç˜¤","ECOG 0-2"],exc:[],out:"PFS:14.6m vs 10.3m; OS:37m vs 29mï¼ˆéåŠ£æ•ˆé”æˆï¼‰"},
{c:"Uterine Sarcoma",p:["R-TX"],s:["Carcinosarcoma"],n:"GOG-161 (Phase III)",ph:"GOG/NCI",d:"Ifosfamide+Paclitaxel",t:"p",pop:"é›™è—¥è¯ç”¨ç²ç›Šï¼šIfosfamide+Paclitaxelæ¯”å–®ç”¨Ifosfamideé¡¯è‘—å»¶é•·PFS(5.8m vs 3.6m)èˆ‡OSã€‚",rat:"é©—è­‰åœ¨IfosfamideåŸºç¤ä¸ŠåŠ å…¥ç´«æ‰é†‡é¡è—¥ç‰©æ˜¯å¦èƒ½å…‹æœUCSçš„åŒ–ç™‚æŠ—è—¥æ€§ã€‚",reg:"è©¦é©—çµ„: Ifosfamide 1.6g/mÂ²(D1-3)+Paclitaxel 135mg/mÂ²(D1) Q3W\nå°ç…§çµ„: Ifosfamideå–®è—¥ 2.0g/mÂ²(D1-3)",inc:["ä¸å¯åˆ‡é™¤ã€æŒä¹…æ€§æˆ–å¾©ç™¼æ€§å­å®®ç™Œè‚‰ç˜¤","å…ˆå‰æœªæ¥å—éé‡å°æ™šæœŸç–¾ç—…ä¹‹åŒ–ç™‚"],exc:[],out:"mPFS:5.8m vs 3.6m(HR 0.71); mOS:13.5m vs 8.4m"},
{c:"Uterine Sarcoma",p:["P-TX"],s:["Carcinosarcoma"],n:"GOG-150 (Phase III)",ph:"GOG/NCI",d:"Adjuvant AP Chemo vs WAI",t:"p",pop:"è¡“å¾Œè¼”åŠ©ç­–ç•¥ï¼šWAIèˆ‡åŒ–ç™‚(AP)æ¯”è¼ƒï¼ŒOSç„¡é¡¯è‘—å·®ç•°ï¼Œä½†åŒ–ç™‚å°Stage I-IIç™Œè‚‰ç˜¤çš„ç³»çµ±æ§åˆ¶åŠ›æ›´ä½³ã€‚",rat:"Stage I-IIç™Œè‚‰ç˜¤å®Œå…¨åˆ‡é™¤å¾Œï¼Œå±€éƒ¨æ”¾ç™‚èˆ‡å…¨èº«åŒ–ç™‚å“ªç¨®èƒ½æ›´æœ‰æ•ˆé™ä½é«˜å¾©ç™¼ç‡ã€‚",reg:"åŒ–ç™‚çµ„: Doxorubicin 60mg/mÂ²+Cisplatin 50mg/mÂ²(AP) Q3W x8\næ”¾ç™‚çµ„: WAI 30Gyåˆ†20æ¬¡ç…§å°„",inc:["å®Œå…¨åˆ‡é™¤ä¹‹Stage Iæˆ–IIå­å®®ç™Œè‚‰ç˜¤","æ‰‹è¡“æ¢æŸ¥è­‰å¯¦ç„¡è…¹è†œå…§è½‰ç§»"],exc:[],out:"å…©çµ„é–“OSç„¡é¡¯è‘—å·®ç•°ï¼ŒAPåŒ–ç™‚çµ„å¾©ç™¼é¢¨éšªæ¯”ç‡å‘ˆä¸‹é™è¶¨å‹¢"},
{c:"Uterine Sarcoma",p:["R-TX"],s:["Recurr / Metastatic"],n:"ET743-SAR-3007",ph:"Janssen",d:"Trabectedin vs Dacarbazine",t:"p",pop:"LMSæ•‘æ´äºŒç·šæ¨™æº–ï¼šTrabectedinç›¸æ¯”Dacarbazineå¯é¡¯è‘—é™ä½45%ç–¾ç—…é€²å±•é¢¨éšª(HR 0.55)ã€‚",rat:"é‡å°å«AnthracyclineåŒ–ç™‚å¤±æ•—çš„æ™šæœŸLMSï¼Œé©—è­‰Trabectedinçš„ç™‚æ•ˆã€‚",reg:"Trabectedin 1.5mg/mÂ²(24hæŒçºŒéœè„ˆæ»´æ³¨) Q3W\nå°ç…§çµ„: Dacarbazine 1000mg/mÂ² Q3W",inc:["ä¸å¯åˆ‡é™¤æˆ–è½‰ç§»æ€§LMSæˆ–è„‚è‚ªè‚‰ç˜¤","å…ˆå‰æ¥å—å«Anthracyclineæ–¹æ¡ˆæ²»ç™‚"],exc:[],out:"LMSæ—ç¾¤mPFS:4.2m vs 1.5m(HR 0.55, P<0.001)ï¼›ITT OSç„¡é¡¯è‘—å·®ç•°"},
{c:"Uterine Sarcoma",p:["R-TX"],s:["Recurr / Metastatic"],n:"PALETTE",ph:"Novartis/GSK",d:"Pazopanib(TKI)",t:"p",pop:"éè„‚è‚ªè‚‰ç˜¤äºŒç·šæ¨™æº–ï¼šPazopanibé¡¯è‘—å»¶é•·ä¸­ä½PFSé”ä¸‰å€(4.6m vs 1.6m, HR 0.31)ã€‚",rat:"å¤šé¶é»TKIæŠ‘åˆ¶VEGFã€PDGFRèˆ‡c-Kité€šè·¯ï¼Œé˜»æ–·è‚‰ç˜¤çš„è¡€ç®¡æ–°ç”Ÿèˆ‡ç”Ÿé•·è¨Šè™Ÿã€‚",reg:"Pazopanib 800mg æ¯æ—¥å£æœä¸€æ¬¡ï¼ŒæŒçºŒç›´åˆ°PDæˆ–ä¸å¯è€å—",inc:["å…ˆå‰åŒ–ç™‚å¤±æ•—ä¹‹æ™šæœŸéè„‚è‚ªè‚‰ç˜¤æ€§è»Ÿçµ„ç¹”è‚‰ç˜¤ï¼ˆå«å­å®®LMSï¼‰","ECOG 0-1"],exc:[],out:"mPFS:4.6m vs 1.6m(HR 0.31, P<0.0001)ï¼›OSå‘ˆç²ç›Šè¶¨å‹¢ä½†æœªé”çµ±è¨ˆé¡¯è‘—"},
{c:"Uterine Sarcoma",p:["R-TX"],s:["Recurr / Metastatic"],n:"REGOSARC",ph:"Bayer",d:"Regorafenib(TKI)",t:"p",pop:"äºŒç·šTKIæ–°æ•¸æ“šï¼šLMSæ—ç¾¤Regorafenibé¡¯è‘—å»¶é•·PFS(HR 0.46)ï¼Œå…·å‚™è‡¨åºŠæ•‘æ´åƒ¹å€¼ã€‚",rat:"éš¨æ©Ÿé›™ç›²å®‰æ…°åŠ‘å°ç…§IIæœŸè©¦é©—ï¼Œé©—è­‰Regorafenibåœ¨å„é¡è‚‰ç˜¤åˆ†å‹ä¸­çš„æ´»æ€§ã€‚",reg:"Regorafenib 160mg QDï¼ˆæœç”¨3é€±ä¼‘æ¯1é€±ï¼‰ï¼Œæ¯28å¤©ç‚ºä¸€é€±æœŸ",inc:["å…ˆå‰æ¥å—å«Anthracyclineæˆ–å¤šç·šæ²»ç™‚å¤±æ•—ä¹‹æ™šæœŸè‚‰ç˜¤","åŒ…å«å­å®®LMSéšŠåˆ—"],exc:[],out:"LMSéšŠåˆ—PFS:4.4m vs 1.4m(HR 0.46, P=0.0045)"},
{c:"Uterine Sarcoma",p:["R-TX"],s:["Recurr / Metastatic"],n:"Eribulin vs Dacarbazine",ph:"Eisai",d:"Eribulin",t:"p",pop:"LMS/LPSå­˜æ´»ç²ç›Šï¼šEribuliné¡¯è‘—å»¶é•·ä¸­ä½OS(13.5m vs 11.5m, HR 0.77)ã€‚",rat:"éå¾®ç®¡è›‹ç™½è§£èšé¡è—¥ç‰©ï¼Œæ¢ç´¢å…¶åœ¨é›£æ²»å‹è‚‰ç˜¤ä¸­å°OSçš„è²¢ç»ã€‚",reg:"Eribulin 1.4mg/mÂ²(D1,D8) Q21d",inc:["å…ˆå‰è‡³å°‘2ç·šæ²»ç™‚ï¼ˆå«Anthracyclineï¼‰å¤±æ•—ä¹‹æ™šæœŸLMSæˆ–LPS","ECOG 0-1"],exc:[],out:"mOS:13.5m vs 11.5m(HR 0.77, P=0.016)"},
{c:"Uterine Sarcoma",p:["R-TX","P-TX"],s:["Recurr / Metastatic","Primary Sarcoma"],n:"NTRK Basket Trials",ph:"Bayer/Roche",d:"Larotrectinib/Entrectinib",t:"p",pop:"è·¨ç™Œåˆ¥ç²¾æº–é†«ç™‚ï¼šå¸¶æœ‰NTRKåŸºå› èåˆçš„è‚‰ç˜¤ï¼ŒLarotrectinibçš„ORRé«˜é”75%ã€‚",rat:"NTRKèåˆç‚ºé«˜åº¦è‡´ç™Œé©…å‹•å› å­ï¼ŒTRKæŠ‘åˆ¶åŠ‘å¯é”æˆæ¥µé«˜ä¸”æŒä¹…çš„è‡¨åºŠåæ‡‰ã€‚",reg:"Larotrectinib 100mg æ¯æ—¥å…©æ¬¡å£æœï¼›æˆ–Entrectinib 600mg æ¯æ—¥ä¸€æ¬¡å£æœ",inc:["NGSè­‰å¯¦å…·å‚™NTRK1/2/3åŸºå› èåˆä¹‹æ™šæœŸå›ºé«”è…«ç˜¤","ç„¡ç¾æœ‰æ¨™æº–æ²»ç™‚æˆ–æ²»ç™‚å¤±æ•—"],exc:[],out:"ITT ORR:~75%; ä¸­ä½PFSé¡¯è‘—å„ªæ–¼å‚³çµ±åŒ–ç™‚"},
{c:"Uterine Sarcoma",p:["R-TX"],s:["Recurr / Metastatic"],n:"Olaparib+Temozolomide (NCT03880019)",ph:"NCI/Columbia",d:"Olaparib+TMZ",t:"p",pop:"uLMSäºŒç·šæ–°çµ„åˆï¼šæ™šæœŸuLMSï¼ŒORRé”27%ï¼Œä¸­ä½PFSç‚º6.9å€‹æœˆã€‚",rat:"TMZèª˜å°DNAæå‚·+Olaparibé˜»æ–·ä¿®å¾©è·¯å¾‘ï¼Œé‡å°uLMSç”¢ç”Ÿåˆæˆè‡´æ­»æ•ˆæ‡‰ã€‚",reg:"Temozolomide 75mg/mÂ² QD(D1-7)+Olaparib 300mg bid(D1-21) Q21d",inc:["çµ„ç¹”å­¸è­‰å¯¦ä¹‹æ™šæœŸuLMS","å…ˆå‰è‡³å°‘ä¸€ç·šç³»çµ±æ²»ç™‚å¾Œé€²å±•"],exc:[],out:"ORR:27%; mPFS:6.9m; CBR:68%"},
{c:"Uterine Sarcoma",p:["R-TX","P-TX"],s:["Low grade ESS"],n:"PARAGON (ANZGOG 0903)",ph:"ANZGOG",d:"Anastrozole",t:"p",pop:"LG-ESSæ¿€ç´ æ²»ç™‚é‡Œç¨‹ç¢‘ï¼šER/PRé™½æ€§æ‚£è€…CBRé«˜é”73.3%ï¼Œä¸­ä½PFSå°šæœªé”åˆ°ã€‚25%æ—ç¾¤PFSè¶…é44å€‹æœˆã€‚",rat:"èŠ³é¦™ç’°è½‰åŒ–é…¶æŠ‘åˆ¶åŠ‘(AI)é˜»æ–·é›Œæ¿€ç´ ç”Ÿæˆï¼Œé‡å°é«˜åº¦æ¿€ç´ ä¾è³´æ€§LG-ESSæä¾›å»åŒ–ç™‚çš„é•·æœŸæ§åˆ¶ã€‚",reg:"Anastrozole 1mg æ¯æ—¥å£æœä¸€æ¬¡ï¼ŒæŒçºŒç›´åˆ°PD",inc:["å¾©ç™¼æ€§æˆ–è½‰ç§»æ€§ER/PR(+)å­å®®å…§è†œé–“è³ªè‚‰ç˜¤(LGESS)","ECOG 0-2","å…·å‚™å¯æ¸¬é‡ç—…ç¶"],exc:[],out:"CBR at 3m:73.3%; ORR:26.7%; 25%æ—ç¾¤PFS>44å€‹æœˆ"},
{c:"Uterine Sarcoma",p:["R-TX","P-TX"],s:["Low grade ESS"],n:"Letrozole (NCT05649956)",ph:"Investigator-Initiated",d:"Letrozole",t:"o",pop:"LG-ESSé•·æœŸç¶­æŒæ–°å¯¦è­‰ï¼šè©•ä¼°Letrozoleåœ¨æ—©æœŸè¡“å¾Œè¼”åŠ©æˆ–æ™šæœŸç¶­æŒä¸­çš„é•·æœŸç™‚æ•ˆèˆ‡å®‰å…¨æ€§ã€‚",rat:"ER/PRé«˜åº¦è¡¨é”çš„é–“è³ªè‚‰ç˜¤ï¼ŒLetrozoleå·²é¡¯ç¤ºå‡ºæ¥µä½³ç·©è§£ç‡èˆ‡ä½æ¯’æ€§ã€‚",reg:"Letrozole 2.5mg æ¯æ—¥å£æœä¸€æ¬¡ï¼Œé•·æœŸæœç”¨ç›´è‡³PD",inc:["æ–°è¨ºæ–·æˆ–å¾©ç™¼æ€§LGESS","ER/PRé™½æ€§"],exc:[],out:"éƒ¨åˆ†å€‹æ¡ˆé¡¯ç¤ºå¯é”7å¹´ä»¥ä¸Šä¹‹ç©©å®šç·©è§£(Stable Disease)"},
{c:"Uterine Sarcoma",p:["P-TX"],s:["Primary Sarcoma"],n:"NCT07076186 (Adjuvant Doxo+Trab)",ph:"Decentralized Pragmatic Trial",d:"Doxorubicin+Trabectedin",t:"o",pop:"æ—©æœŸè¼”åŠ©å¼·åŒ–ç ”ç©¶ï¼šStage Ib/2 uLMSè¡“å¾Œä½¿ç”¨Doxo+Trabæ˜¯å¦èƒ½é¡¯è‘—å»¶é•·ç„¡ç—…ç”Ÿå­˜æœŸã€‚",rat:"åŸºæ–¼LMS-04è©¦é©—æˆåŠŸï¼Œå°‡Doxoè¯ç”¨Trabectedinæå‰è‡³è¼”åŠ©æ²»ç™‚éšæ®µä»¥é™ä½é«˜å¾©ç™¼é¢¨éšªã€‚",reg:"Doxorubicin 60mg/mÂ²+Trabectedin 1.1mg/mÂ² Q21d â†’ Trabectedinç¶­æŒ",inc:["Stage Ibæˆ–IIæœŸå­å®®å¹³æ»‘è‚Œè‚‰ç˜¤(uLMS)","æ‰‹è¡“å®Œå…¨åˆ‡é™¤(R0)å¾Œ3å€‹æœˆå…§"],exc:[],out:"è©¦é©—é€²è¡Œä¸­(Ongoing)ï¼Œé è¨ˆ2025å¹´åº•é–‹å§‹æ­£å¼æ”¶æ¡ˆ"}
];

const GUIDELINES={
"Endometrial":[
{id:"P-TX",header:"ğŸŒ¿ åˆæ²» (Primary Tx)",css:"p-tx",subs:[
{title:"dMMR / MSI-H / MMRd",content:"ä¸€ç·šé¦–é¸ï¼šå«é‰‘åŒ–ç™‚ + PD-1 (RUBY/GY018/AtTEnd)ã€‚"},
{title:"pMMR / NSMP / MSS",content:"ä¸€ç·šç¶­æŒï¼šChemo + Durva/Ola (DUO-E)ã€‚äºŒç·šæ¨™é¶å…ç–« (KN775)ã€‚"},
{title:"POLE mutation (è¶…çªè®Šå‹)",content:"é å¾Œæ¥µä½³ã€‚æ—©æœŸå¯è€ƒæ…®æ²»ç™‚é™éš (De-escalation)ã€‚RAINBO BLUEã€‚"},
{title:"p53 mutation (é«˜æ‹·è²å‹)",content:"ä¾µè¥²æ€§æœ€å¼·ã€‚å»ºè­°åŒ–æ”¾ç™‚ç©æ¥µä»‹å…¥ã€‚Serouså‹éœ€æª¢æ¸¬HER2ã€‚RAINBO REDã€‚"}]},
{id:"P-MT",header:"ğŸ’Š ä¸€ç·šç¶­æŒ (1L Maint)",css:"p-mt",subs:[
{title:"Maintenance Therapy",content:"ä¸€ç·šIOæ²»ç™‚å¾Œå»¶çºŒç¶­æŒè‡³PD (MK2870-033/DUO-E/SIENDO)ã€‚"}]},
{id:"R-TX",header:"ğŸ”„ å¾©ç™¼æ²»ç™‚ (Recurr Tx)",css:"r-tx",subs:[
{title:"Recurrent EC",content:"æ¨™æº–äºŒç·šï¼šæ¨™é¶+å…ç–« (KN775) æˆ–å–®è—¥IO (GARNET)ã€‚æ•‘æ´ADC (SG/Trodelvy)ã€‚"}]},
{id:"R-MT",header:"ğŸ”’ å¾©å¾Œç¶­æŒ (PR-Maint)",css:"r-mt",subs:[
{title:"Continuous Therapy",content:"æ•‘æ´æ²»ç™‚å¾Œç¶­æŒç•¶å‰æœ‰æ•ˆæ–¹æ¡ˆç›´åˆ°ç–¾ç—…é€²å±•ã€‚"}]}
],
"Ovarian":[
{id:"P-TX",header:"ğŸŒ¿ åˆæ²» (Primary Tx)",css:"p-tx",subs:[
{title:"Neoadjuvant Setting",content:"NACT vs PDS (EORTC/CHORUS/SCORPION/JCOG0602/TRUST)ã€‚NACT+IDS+HIPEC(van Driel)ã€‚"},
{title:"DDCT Setting",content:"Dose-Dense Chemo (JGOG3016/GOG-262/ICON8/MITO-7)ã€‚"},
{title:"IP Setting",content:"IP Cisplatin/Paclitaxel (GOG-172)ã€‚GOG-252(with Bev)ã€‚OV21/PETROCã€‚"},
{title:"HGSC / Endometrioid",content:"æ‰‹è¡“(PDS/IDS)+Carbo/PacliÂ±Bev(GOG-0218/ICON7)ã€‚LION(LN-é™°æ€§å…æ¸…æƒ)ã€‚"},
{title:"Low grade serous carcinoma",content:"AI, MEK, CDK 4/6ã€‚NRG-GY019é€²è¡Œä¸­ã€‚"},
{title:"Clear Cell Carcinoma",content:"OCCCã€‚JGOG3017æ¯”è¼ƒä¸€ç·šæ–¹æ¡ˆã€‚"},
{title:"Mucinous (MOC) é‘‘å®š",content:"CK7+/SATB2-(åŸç™¼)ã€‚è€ƒæ…®GI-styleåŒ–ç™‚æ–¹æ¡ˆ(mEOC/GOG-0241)ã€‚"}]},
{id:"P-MT",header:"ğŸ’Š ä¸€ç·šç¶­æŒ (1L Maint)",css:"p-mt",subs:[
{title:"BRCA mutation",content:"Olaparibå–®è—¥ç¶­æŒ2å¹´(SOLO-1)ã€‚T-DXd(HER2)ç¶­æŒè©¦é©—(DS8201-772)ã€‚"},
{title:"HRD positive (wt)",content:"PAOLA-1(Ola+Bev) æˆ– PRIMA(Nira) æˆ– DUO-O(Durva+Ola+Bev)ã€‚"},
{title:"HRD negative (pHRD)",content:"Niraparibç¶­æŒ(PRIMA ITT)æˆ–Bevacizumab(GOG-0218/ICON7)ã€‚"},
{title:"Clear Cell Carcinoma",content:"OCCCã€‚Temsirolimusç¶­æŒPhase IIè³‡æ–™ã€‚"}]},
{id:"R-TX",header:"ğŸ”„ å¾©ç™¼æ²»ç™‚ (Recurr Tx)",css:"r-tx",subs:[
{title:"PSOC (Sensitive Recur)",content:"PFI>6mã€‚è©•ä¼°äºŒæ¬¡æ‰‹è¡“(DESKTOP III)æˆ–å«é‰‘è¤‡æ–¹+Bev(OCEANS/GOG-0213/MITO16B)ã€‚Calypsoã€‚"},
{title:"PROC (Resistant Recur)",content:"PFI<6mã€‚å–®è—¥åŒ–ç™‚Â±Bev(AURELIA)æˆ–FRÎ± ADC(MIRASOL/FRAmework-01)ã€‚"},
{title:"Low grade serous carcinoma",content:"Trametinib(GOG-281)ã€Ribociclib+Let(GOG-3026)ã€Avutometinib+Def(RAMP-201)ã€‚"},
{title:"Clear Cell Carcinoma",content:"OCCCã€‚Nivo+Ipi(MoST-CIRCUIT)ã€CeralasertibÂ±Ola(ATARI)ã€Dostarlimab+Bev(DOVE)ã€‚"},
{title:"Mucinous (MOC) é‘‘å®š",content:"è€ƒæ…®GI-styleæ–¹æ¡ˆã€‚mFOLFIRINOX+Bevè©¦é©—é€²è¡Œä¸­ã€‚"}]},
{id:"R-MT",header:"ğŸ”’ å¾©å¾Œç¶­æŒ (PR-Maint)",css:"r-mt",subs:[
{title:"PARPi Maint",content:"æ•‘æ´ç·©è§£å¾ŒçºŒç”¨PARPi(NOVA/ARIEL3/SOLO2)ã€‚"}]}
],
"Cervical":[
{id:"P-TX",header:"ğŸŒ¿ åˆæ²» (Primary Tx)",css:"p-tx",subs:[
{title:"Locally Advanced (CCRT)",content:"åŒæ­¥åŒ–æ”¾ç™‚Â±åŒæ­¥IO(KN-A18)æˆ–èª˜å°åŒ–ç™‚(INTERLACE)ã€‚CALLAé™°æ€§/OUTBACKé™°æ€§ã€‚"},
{title:"Locally Advanced (NIC)",content:"æ–°è¼”åŠ©å…ç–«+åŒ–ç™‚â†’æ‰‹è¡“(NACI/NATIC/Cadonilimab)ã€‚"},
{title:"Early Stage (Surgery)",content:"æ ¹æ²»è¡“é–‹è…¹å„ªå…ˆ(LACC)ã€‚ä½é¢¨éšªå¯å–®ç´”åˆ‡é™¤(SHAPE)ã€‚"}]},
{id:"P-MT",header:"ğŸ’Š ä¸€ç·šç¶­æŒ (1L Maint)",css:"p-mt",subs:[
{title:"Maintenance",content:"1Læ–¹æ¡ˆå¾Œæ¥çºŒç¶­æŒ(KEYNOTE-826)ã€‚"}]},
{id:"R-TX",header:"ğŸ”„ å¾©ç™¼æ²»ç™‚ (Recurr Tx)",css:"r-tx",subs:[
{title:"Recurr / Metastatic",content:"ä¸€ç·šKN826/BEATcc/GOG-240+Bevã€‚äºŒç·šADC(innovaTV 301)æˆ–IO(EMPOWER/Cemiplimab)ã€‚"}]},
{id:"R-MT",header:"ğŸ”’ å¾©å¾Œç¶­æŒ (PR-Maint)",css:"r-mt",subs:[
{title:"Continuous Therapy",content:"ç¶­æŒç•¶å‰æœ‰æ•ˆæ•‘æ´æ–¹æ¡ˆç›´è‡³PDã€‚"}]}
],
"Uterine Sarcoma":[
{id:"P-TX",header:"ğŸŒ¿ åˆæ²» (Primary Tx)",css:"p-tx",subs:[
{title:"Primary Sarcoma",content:"è¡“å¾Œè¼”åŠ©æˆ–è½‰ç§»æ€§ã€‚DoxÂ±Ifo(EORTC62012)ã€‚GeDDiSç¢ºèªDoxç‚ºåŸºæº–ã€‚LMS-04(Dox+Trab)ã€‚"},
{title:"Carcinosarcoma",content:"PCæ–¹æ¡ˆç‚ºæ–°æ¨™æº–(GOG-0261)ã€‚æˆ–Pacli/Ifo(GOG-161)ã€‚GOG-150è¼”åŠ©è³‡æ–™ã€‚"},
{title:"Low grade ESS",content:"æ¿€ç´ æ²»ç™‚å„ªå…ˆï¼šAnastrozole(PARAGON)ã€‚Letrozole(NCT05649956é€²è¡Œä¸­)ã€‚"}]},
{id:"P-MT",header:"ğŸ’Š ä¸€ç·šç¶­æŒ (1L Maint)",css:"p-mt",subs:[
{title:"Maintenance",content:"LMS: Trabectedinç¶­æŒ(LMS-04)ã€‚LGESS: æŒçºŒæ¿€ç´ æ²»ç™‚ã€‚NCT07076186è¼”åŠ©è©¦é©—é€²è¡Œä¸­ã€‚"}]},
{id:"R-TX",header:"ğŸ”„ å¾©ç™¼æ²»ç™‚ (Recurr Tx)",css:"r-tx",subs:[
{title:"Recurr / Metastatic",content:"LMS: Trabectedin(ET743)ã€Pazopanib(PALETTE)ã€Regorafenib(REGOSARC)ã€Eribulinã€Ola+TMZã€‚"},
{title:"Carcinosarcoma",content:"PCæ–¹æ¡ˆ(GOG-0261)ã€‚GOG-161 Ifo+Pacliã€‚"},
{title:"Low grade ESS",content:"æ¿€ç´ æ²»ç™‚ç‚ºä¸»(PARAGON/Letrozole)ã€‚NTRKèåˆ: Larotrectinib/Entrectinibã€‚"}]},
{id:"R-MT",header:"ğŸ”’ å¾©å¾Œç¶­æŒ (PR-Maint)",css:"r-mt",subs:[
{title:"Continuous Therapy",content:"ç¶­æŒç•¶å‰æœ‰æ•ˆæ•‘æ´æ–¹æ¡ˆç›´è‡³PDã€‚LMS: è€ƒæ…®Olaparib+TMZã€‚NTRKèåˆ: Larotrectinib/Entrectinibã€‚"}]}
]
};

let currentCancer='Endometrial';

function selectCancer(cancer,btn){
  currentCancer=cancer;
  document.querySelectorAll('.cancer-btn').forEach(b=>b.classList.remove('active'));
  btn.classList.add('active');
  renderGrid(cancer);
}

function matchTrial(t,stageId,subTitle){
  if(!t.p.includes(stageId))return false;
  const clean=w=>w.replace(/\(.*?\)/g,'').trim().toLowerCase();
  const ct=clean(subTitle);
  return t.s.some(s=>{
    const cs=clean(s);
    return ct.includes(cs)||cs.includes(ct)||subTitle.includes(s.split('(')[0].trim())||s.includes(subTitle.split('(')[0].trim());
  });
}

function renderGrid(cancer){
  const grid=document.getElementById('stage-grid');
  const stages=GUIDELINES[cancer];
  if(!stages)return;
  grid.innerHTML=stages.map(stage=>{
    const subsHTML=stage.subs.map(sub=>{
      const trials=TRIALS.filter(t=>t.c===cancer&&matchTrial(t,stage.id,sub.title));
      const chips=trials.map(t=>{
        const encoded=encodeURIComponent(JSON.stringify(t));
        const isO=t.t==='o';
        return `<button class="trial-chip${isO?' ongoing':''}" data-t="${encoded}" onclick="openModal(this)">
          ${isO?'ğŸ“':'ğŸ“š'} ${t.n}
          <span class="chip-pharma">${t.ph} Â· ${t.d}</span>
        </button>`;
      }).join('');
      return `<div class="sub-section">
        <div class="sub-title">ğŸ“˜ ${sub.title}</div>
        <div class="sub-content">${sub.content}</div>
        ${chips}
      </div>`;
    }).join('');
    return `<div class="stage-col stage-${stage.css}">
      <div class="stage-header">${stage.header}</div>
      ${subsHTML}
    </div>`;
  }).join('');
}

function openModal(btn){
  const t=JSON.parse(decodeURIComponent(btn.getAttribute('data-t')));
  document.getElementById('modalTitle').textContent=t.n;
  document.getElementById('modalDrug').textContent=t.d;
  document.getElementById('modalPharma').textContent=t.ph;
  document.getElementById('modalResults').textContent=t.pop;
  document.getElementById('modalRationale').textContent=t.rat;
  document.getElementById('modalRegimen').textContent=t.reg;
  document.getElementById('modalInclusion').innerHTML=(t.inc||[]).map(i=>`<li>${i}</li>`).join('');
  document.getElementById('modalExclusion').innerHTML=(t.exc||[]).map(e=>`<li>${e}</li>`).join('');
  document.getElementById('detailOverlay').classList.add('open');
  document.body.style.overflow='hidden';
}
function closeModal(e,force){
  if(force||!e||e.target===document.getElementById('detailOverlay')){
    document.getElementById('detailOverlay').classList.remove('open');
    document.body.style.overflow='';
  }
}
function switchTab(tab,btn,src){
  document.querySelectorAll('.tab-panel').forEach(p=>p.classList.remove('active'));
  document.getElementById('tab-'+tab).classList.add('active');
  document.querySelectorAll('.nav-btn').forEach(b=>b.classList.remove('active'));
  document.querySelectorAll('.mobile-nav-btn').forEach(b=>b.classList.remove('active'));
  if(src==='mobile'){document.getElementById('mnav-'+tab).classList.add('active');}
  else{if(btn)btn.classList.add('active');document.getElementById('mnav-'+tab).classList.add('active');}
  window.scrollTo({top:0,behavior:'smooth'});
}
function switchMode(mode,btn){
  ['text','image','form'].forEach(m=>{document.getElementById('mode-'+m).style.display=m===mode?'block':'none';});
  document.querySelectorAll('.mode-tab').forEach(b=>b.classList.remove('active'));
  btn.classList.add('active');
}
let imgB64=null,imgMime=null;
function handleImageUpload(event){
  const file=event.target.files[0];if(!file)return;
  const reader=new FileReader();
  reader.onload=(e)=>{
    const r=e.target.result;
    imgB64=r.split(',')[1];imgMime=file.type;
    document.getElementById('previewImg').src=r;
    document.getElementById('previewName').textContent='âœ… '+file.name+' ('+(file.size/1024).toFixed(0)+' KB)';
    document.getElementById('uploadedPreview').classList.add('show');
  };
  reader.readAsDataURL(file);
}
const uz=document.getElementById('uploadZone');
if(uz){
  uz.addEventListener('dragover',e=>{e.preventDefault();uz.style.borderColor='var(--teal)';});
  uz.addEventListener('dragleave',()=>{uz.style.borderColor='';});
  uz.addEventListener('drop',e=>{
    e.preventDefault();uz.style.borderColor='';
    const file=e.dataTransfer.files[0];
    if(file){document.getElementById('imgUpload').files=e.dataTransfer.files;handleImageUpload({target:{files:[file]}});}
  });
}

const SYS_PROMPT=`ä½ æ˜¯ä¸€ä½è³‡æ·±å©¦ç§‘è…«ç˜¤è‡¨åºŠé†«å¸«ï¼ŒåŒæ™‚ä¹Ÿæ˜¯è‡¨åºŠè©¦é©—è¨­è¨ˆå°ˆå®¶ã€‚æ ¹æ“šä»¥ä¸‹å©¦ç™Œè‡¨åºŠè©¦é©—å¯¦è­‰è³‡æ–™åº«ï¼Œé‡å°æ‚£è€…ç—…æ­·è³‡æ–™é€²è¡Œæ·±åº¦åˆ†æï¼Œæä¾›ï¼š
ã€åˆ†å­åˆ†å‹è§£è®€ã€‘æ ¹æ“šè¼¸å…¥çš„æ¨™è¨˜ï¼ˆMMRã€p53ã€POLEã€BRCAã€HRDç­‰ï¼‰ï¼Œåˆ¤æ–·æ‚£è€…åˆ†å­äºå‹åŠå…¶é å¾Œæ„ç¾©ã€‚
ã€æ¨è–¦æ²»ç™‚è·¯å¾‘ã€‘ä¾æ“šç›®å‰å¯¦è­‰æœ€å¼·çš„æ–¹æ¡ˆï¼Œæä¾›åˆ†æœŸåˆ†ç·šçš„å…·é«”å»ºè­°ï¼ˆè«‹å¼•ç”¨è©¦é©—åç¨±å¦‚RUBYã€KN775ç­‰ï¼‰ã€‚
ã€å¯åƒèˆ‡è‡¨åºŠè©¦é©—ã€‘åˆ—å‡ºç¬¦åˆæ¢ä»¶çš„é€²è¡Œä¸­è©¦é©—ï¼ˆæ¨™è¨˜ğŸ“è€…ï¼‰ï¼Œèªªæ˜ç¬¦åˆåŸå› ã€‚
ã€é¢¨éšªèˆ‡æ³¨æ„äº‹é …ã€‘å…ç–«ç›¸é—œå‰¯ä½œç”¨ã€PARPiè¡€æ¶²æ¯’æ€§ã€ADCçœ¼æ¯’æ€§ç­‰å€‹åˆ¥åŒ–æ³¨æ„äº‹é …ã€‚
è«‹ä½¿ç”¨ç¹é«”ä¸­æ–‡ï¼Œå›ç­”è¦ç²¾æº–ä¸”æœ‰æ¢ç†ï¼Œç”¨é†«å¸«å°é†«å¸«çš„èªæ°£ï¼Œä¸éœ€éåº¦è§£é‡‹åŸºç¤çŸ¥è­˜ã€‚`;

async function runAnalysis(){
  const apiKey=document.getElementById('apiKey').value.trim();
  if(!apiKey){alert('è«‹å…ˆè¼¸å…¥ Gemini API Keyã€‚');return;}
  const activeMode=document.querySelector('.mode-tab.active').textContent.trim();
  let userContent='';
  if(activeMode.includes('æ–‡å­—')){
    userContent=document.getElementById('textInput').value.trim();
    if(!userContent){alert('è«‹è¼¸å…¥æ‚£è€…ç—…æ­·æ‘˜è¦ã€‚');return;}
  }else if(activeMode.includes('å½±åƒ')){
    if(!imgB64){alert('è«‹å…ˆä¸Šå‚³å½±åƒæª”æ¡ˆã€‚');return;}
    userContent=document.getElementById('imageContextInput').value||'è«‹åˆ†ææ­¤ç—…ç†/å½±åƒåœ–ç‰‡ï¼Œä¸¦æ ¹æ“šå©¦ç™Œè©¦é©—è³‡æ–™åº«çµ¦å‡ºæ²»ç™‚å»ºè­°ã€‚';
  }else{
    const cancer=document.getElementById('f-cancer').value;
    const stage=document.getElementById('f-stage').value;
    const mmr=document.getElementById('f-mmr').value;
    const p53=document.getElementById('f-p53').value;
    const pole=document.getElementById('f-pole').value;
    const brca=document.getElementById('f-brca').value;
    const ecog=document.getElementById('f-ecog').value;
    const histo=document.getElementById('f-histo').value;
    const prior=document.getElementById('f-prior').value;
    const markers=document.getElementById('f-markers').value;
    userContent=`ç™Œç—‡:${cancer}|åˆ†æœŸ:${stage}|MMR:${mmr}|p53:${p53}|POLE:${pole}|BRCA/HRD:${brca}|ECOG:${ecog}|çµ„ç¹”å‹æ…‹:${histo}|æ—¢å¾€æ²»ç™‚:${prior}|å…¶ä»–æ¨™è¨˜:${markers}`;
  }
  const btn=document.getElementById('analyzeBtn');
  btn.disabled=true;
  document.getElementById('btnIcon').innerHTML='<div class="spinner"></div>';
  document.getElementById('btnText').textContent='Gemini AI åˆ†æä¸­â€¦';
  const trialSummary=TRIALS.map(t=>`[${t.n}][${t.c}/${t.p}] ${t.pop}`).join('\n');
  const fullPrompt=SYS_PROMPT+'\n\n===è©¦é©—è³‡æ–™åº«æ‘˜è¦===\n'+trialSummary+'\n\n===æ‚£è€…è³‡æ–™===\n'+userContent;
  let requestBody;
  if(imgB64&&activeMode.includes('å½±åƒ')){
    requestBody={contents:[{parts:[{text:fullPrompt},{inline_data:{mime_type:imgMime,data:imgB64}}]}]};
  }else{
    requestBody={contents:[{parts:[{text:fullPrompt}]}]};
  }
  try{
    const res=await fetch(`https://generativelanguage.googleapis.com/v1beta/models/gemini-2.0-flash:generateContent?key=${apiKey}`,
      {method:'POST',headers:{'Content-Type':'application/json'},body:JSON.stringify(requestBody)});
    if(!res.ok){const err=await res.json();throw new Error(err.error?.message||`HTTP ${res.status}`);}
    const data=await res.json();
    const text=data.candidates?.[0]?.content?.parts?.[0]?.text||'ç„¡æ³•å–å¾—å›æ‡‰ã€‚';
    displayResult(text);
  }catch(err){
    alert('âŒ åˆ†æå¤±æ•—ï¼š'+err.message+'\n\nè«‹ç¢ºèª API Key æ˜¯å¦æ­£ç¢ºï¼Œæˆ–ç¶²è·¯æ˜¯å¦å…è¨±é€£æ¥ Google APIã€‚');
  }finally{
    btn.disabled=false;
    document.getElementById('btnIcon').textContent='âœ¨';
    document.getElementById('btnText').textContent='å•Ÿå‹• Gemini AI åˆ†æ';
  }
}
function displayResult(text){
  const contentDiv=document.getElementById('resultContent');
  let html=text
    .replace(/\*\*(.+?)\*\*/g,'<strong>$1</strong>')
    .replace(/^#{1,3}\s(.+)$/gm,'<h4>$1</h4>')
    .replace(/^[-â€¢]\s(.+)$/gm,'<li>$1</li>')
    .replace(/(<li>.*<\/li>\n?)+/g,m=>`<ul>${m}</ul>`)
    .replace(/\n\n/g,'</p><p>')
    .replace(/\n/g,'<br>');
  contentDiv.innerHTML=`<p>${html}</p>`;
  const rd=document.getElementById('aiResult');
  rd.classList.add('show');
  rd.scrollIntoView({behavior:'smooth',block:'start'});
}
renderGrid('Endometrial');
</script>
</body>
</html>